BIOTECH FRANCE |
|
| Quick Click ! | Monthly news | Home-Site | Contactexpress | Faqs | Legends | Search | Companies | Events | Environment | Memories | Home-Biotech |
|---|
|
|
|
|
|
Abcys | ABScience | Adocia | AdvicennePharma | Affichem | AgateBioservices | AisaTherapeutics | AlfactInnovation | AliX | AlizePharma | Alphelys | Ambiotis | AnacondaPharma | AptysPharmaceuticals | ArianaPharmaceuticals | AtlanticBoneScreen | AureusPharma | BCellDesign | BioAlliancePharma | Biocortech | BioCydex | BioMedicalDiagnostics | Biomethodes | Biomup | BioProteinTechnologies | BioQuanta | BioSystemsInternational | BMSystems | BTPharma | Carmat | Cellectis | CellialTechnologies | CellVax | CellVir | CerenisTherapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytomics | Cytoo | DBVTechnologies | DNATherapeutics | DomainTherapeutics | Dynabio | EchoSens | Edelris | EndotisPharma | Epixis | ERYtechPharma | Exonhit | EyeTechCare | FlamelTechnologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | GenOdyssee | GenomicVision | GenoSafe | GenoSciencePharma | Genoscreen | GenOway | GTPTechnology | HeliosBiosciences | Hybrigenics | HyphenBioMed | Imagene | ImmunId | Immutep | Imstar | InCellArt | IndiciaBiotechnology | InGenBiosciences (AbAg) | InnatePharma | InnaVirVax | InnovativeHealthDiagnostics | IntegraGen | Ipsogen | IStem | Karcinolys | Keosys | LibraGen | Magnisense | Mapreg | MATBiopharma | MaunaKeaTechnologies | MedesisPharma | Mellitech | Metabolys | MicroBioChips | MilleGen | MitoProd | Murigenetics | Mutabilis | Myosix | NanoBiotix | Neorphys | Neovacs | NetrisPharma | Neuronax | NicOx | Nokad | Nosopharm | NovaDecision | Novagali | NovoCIB | Novotec | ObeTherapy | Oligovax | Oncodesign | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | PherecydesPharma | PolyIntell | PraXcell | Proteogenix | Proteus | Protexel | PXTherapeutics | QuantumGenomics | RhenoviaPharma | ScarCellTherapeutics | SepalPharma | SerialGenetics | ShigaMediX | SiseneBiotechnologies | SkuldTech | Synapcell | Synprosis | TcLandExpression | Theraclion | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Urrma | VaxonBiotech | Vectalys | VigiCell | Vivalis | XenTech | ZetaBiotech |
| COMPANY | YEAR | LOCATION | BUSINESS MODEL | MANAGEMENT | TOT-M€ | LAST-M€ | FOCUS | STAGE |
|---|---|---|---|---|---|---|---|---|
| Abcys Profile + www.abcysonline.com | 1999 | IDF Paris | Design, Reagents Key words: Immunology, Cytokines, Cell culture, Stem cells, Production, Distribution, Third Parties, Gemstem Mission: to design, manufacture and distribute biotechnology reagents, and to develop own research on Stem Cells Clients: Research institutes, Hospitals, Universities, Pharmaceutical industry, Diagnostic industry Age: 10 year(s) | Start-up | Managing Dir.-CEO: Martin (Thierry) [born 1961] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): undisclosed Communication : no website corporate information or press release since 2006 | n.a. | n.a. | Cell | Trade |
| AB Science Profile + www.ab-science.com | 2001 | IDF Paris | Discovery, Drugs Key words: Mastocytosis, Inhibitors, Tyrosine Kinase, Anticancer, Inflammation, Auto-immune diseases Mission: to develop innovative tyrosine kinase inhibitors for auto-immune diseases in man and animals Clients: Prescribers, Veterinarians Age: 8 year(s) | Start-up | Managing Dir.-CEO: Moussy (Alain) [founder, born 1965, MBA Wharton, ENSTA, ex-Carrefour (Dir M&A)] Sc.Dir.-CSO: Fin.Dir.-CFO: Guy (Laurent) BusDev: Financers (Hist.): privately owned (registered capital 2007 = 0.29 M€) | 30.0 (estim.) | n.a. | Cancers | Clinical |
| Adocia Profile + www.no-website.net | 2005 | Rhône-Alpes Lyon | Discovery, Drugs Key words: Growth factors, Natural proteins, Regenerating organs, Osteoporosis, Diabetes, Aging population, BioChaperone Mission: to develop innovative drugs for regenerating organs affected by diseases related to the aging of the population, such as osteoporosis and diabetes Clients: Pharmaceutical industry Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Soula (Gérard) [born 1945, ex-Rhône Poulenc, Flamel Technologies (founder)] Sc.Dir.-CSO: Soula (Olivier) [born 1970, PhD polymer science, MBA-IAE (Lyon), ex-Flamel Technologies] Fin.Dir.-CFO: Danaguezian (Valérie) BusDev: Financers (Hist.): AGF P.E., Bioam Gestion, Société Générale A.M., Viveris Management, Business angels (Alain Tornier and Jean Deléage), InnoBio, SHAM (Société Hospitalière d’Assurances Mutuelles) | 27.6 | 14.0 | Multiple | Preclin |
| Advicenne Pharma Profile + www.advicenne.com | 2007 | Méditerranée Castries (near Nîmes) | Discovery, Drugs Key words: CNS, Pediatry, Emergent diseases Mission: development and marketing of drugs for pediatric use mainly for the treatment of Central Nervous System Diseases (including autism, feeding behaviours dysfunctions and neurodegenerative disorders) Clients: undisclosed Age: 2 year(s) | Personal venture | Managing Dir.-CEO: Granier (Luc-André) [founder, born 1954, Ph.D., M.D., ex-Forenap, Eli Lilly, Syntem] Oper.Dir.: Roussel-Maupetit (Caroline) [born 1969, Eng., ex-Syntem (co-founder), Protéine Performance] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2007 = 0.13 M€) | n.a. | n.a. | CNS | Preclin |
| Affichem Profile + www.affichem.com | 2002 | Midi-Pyrénées Toulouse | Design, Drugs (also Design, Diagnostics) Key words: Proteins, Dendrogenins, Cancer, Degenerative diseases Mission: to develop drug candidates based on proprietary new family of compounds derived from sterols, Dendrogenines A and B, in cancer and degenerative illnesses Clients: Prescribers Age: 7 year(s) | Start-up | Managing Dir.-CEO: Silvente (Stéphane) [co-founder, born 1968, MBA, Ms. International Business] Sc.Dir.-CSO: Poirot (Marc) [co-founder, also Inserm, Ph.D. chemical biology] Pharm.Dir.: Silvente-Poirot (Sandrine) [co-founder, also Inserm, Ph.D. molecular pharmacology] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned, undisclosed | n.a. | n.a. | Cancers | Preclin |
| Agate Bioservices Profile + www.agatebioservices.com | 2005 | Méditerranée Alès (near Nîmes) | Contract, Services (also, Discovery, Targets) Key words: Gene expression, Protein production, Gene delivery, Insect cells expression, Baculovirus, BacTen Mission: to provide third parties with services ranging from gene cloning to protein (or virus) production (resp. purification), acting as a vector developer, either for protein production or for gene transfer, as well as a manufacturing partner, to to develop new systems and technologies in the gene expression, gene transfer and delivery areas Clients: Pharmaceutical industry, Biotech, Research labs Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Chaabihi (Hassan) [founder, born 1962, Ph.D. molecular biology, ex-Protéines Performance, Quantum Biotechnologies] Sc.Dir.-CSO: Chaabihi (Hassan) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.008 M€) Communication : no website news update since November 2006 | n.a. | n.a. | Target | Preclin |
| Aisa Therapeutics Profile + www.aisa-tx.com | 2005 | IDF Évry (near Paris) | Discovery, Drugs Key words: Vascular endothelium, Inflammation, Nanomolarity, Colitis, Cystic cancer, Nutraceuticals, Anti-stress Mission: to develop new anti-inflammatory molecules for rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading, based on the modulation-inhibition process in vascular permeability Clients: pharmaceutical industry, veterinary industry Age: 4 year(s) | Personal venture | Managing Dir.-CEO: d'Alessio (Patrizia) [founder, born 1952, M.D., Ph.D., ex-Inserm] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Critt Chimie, Anvar | n.a. | n.a. | Inflammation | Preclin |
| Alfact Innovation Profile + alfactinnovation.com | 2006 | IDF Paris | Discovery, Drugs Key words: Liver Failure, Liver Cancer Mission: to develop biopharmaceuticals for liver diseases Clients: undisclosed Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Amouyal (Gilles) [born 1957, M.D., Ph.D.] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): unknown (registered capital 2008 = 1.48 M€) | n.a. | n.a. | Cancers | Preclin |
| AliX Profile + www.alix-pharma.com | 2002 | Alsace Strasbourg-Illkirch | Discovery, Drugs (also Design, Protein) Key words: NHR (Nuclear Hormone Receptors), Ligands, Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage Mission: to discover, from early-stage, drugs based structure-based design using X-ray crystallography, with a main interest in nuclear hormone receptors, for cancers, type II diabetes, obesity and other metabolic diseases, also for neglected diseases such as schistosomiases, and to provide third parties with service activities in protein crystallization protein crystallography, and ligand screening using mass spectrometry Clients: Research labs Age: 7 year(s) | Spin-off | Managing Dir.-CEO: Zeyer (Denis) [born 1972, Ph.D., ex-IGBMC] Sc.Dir.-CSO: Zeyer (Denis) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€) Note: Alix has become, end of 2008, a subsidiary of Novalix | n.a. | n.a. | Multiple | Preclin |
| Alizé Pharma Profile + www.alz-pharma.com | 2007 | Rhône-Alpes Ecully (near Lyon) | Discovery, Drugs Key words: Diabetes, Leukaemia, Recombinant L-asparaginase Mission: to develop innovative therapeutics for the treatment of metabolic diseases and cancers (after early acquisition of products from Biotechs and in-house preliminary development) Clients: Pharmaceutical industry Age: 2 year(s) | Start-up | Managing Dir.-CEO: Abribat (Thierry) [co-founder, born 1964, Ph.D., Vet.D., ex-Sanofi-Recherche, Theratechnologies, OPi (CEO)] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Octalfa (Gilles Alberici, board member), CEMA (Canada, André de Villers, board member), SHAM (registered capital 2007 = 0.052 M€) | 4.8 | 3.0 | Multiple | Preclin |
| Alphelys Profile + www.alphelys.com | 2001 | IDF Plaisir (near Paris) | Design, Solutions Key words: Instruments, Tissue array, Molecular histology, Imaging, Software, Reagents, Tisalys, Cresalys, MiniCore Mission: to design, develop and market innovative integrated solutions including instruments, software and reagents for pathology and cytogenetics markets Clients: Pharmaceutical industry, Research labs Age: 8 year(s) | Personal venture | Managing Dir.-CEO: Chaumat (Pierre) [co-founder, born 1965] Sc.Dir.-CSO: SalesMktg: Defrenaix (Pierre) [co-founder] Fin.Dir.-CFO: BusDev: Financers (Hist.): none (100% privately owned, capital 2007 = 0.04 M€, 2006 = 0.11 M€) | 0.4 | n.a. | Multiple | Preclin |
| Ambiotis Profile + www.ambiotis.com | 2007 | Midi-Pyrénées Toulouse | Contract, Services (also, Research, Drugs) Key words: Validation, Anti-inflammatory, Immunostimulatory, Biomarkers Mission: to provide preclinical testing services (cellular and animal experiments) for anti-inflammatory and immunostimulatory assays of third parties, and to undertake own research specialized in the study of lipoxins, resolvins and protectins Clients: Pharmaceutical industry, Cosmetics, Nutraceutics, Agro-food Age: 2 year(s) | Personal venture | Managing Dir.-CEO: Dubourdeau (Marc) [founder, born 1973, M.D., Ph.D. Immunology, Ms. Management (Toulouse)] Sc.Dir.-CSO: Dubourdeau (Marc) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2007 = 0.04 M€) | n.a. | n.a. | Inflammation | Subcontractor |
| Anaconda Pharma Profile + www.anacondapharma.com | 2003 | IDF Paris | Discovery, Drugs Key words: Protein interactions, Condyloma, Anti-viral Mission: to develop a proprietary platform for the discovery of small molecules that disrupt protein:protein interactions, as a distinct unexploited class of pharmaceutical targets, due to the difficulty of recognizing drugable hot-spots on the surface of interacting proteins Clients: Prescribers Age: 6 year(s) | Spin-off | Managing Dir.-CEO: Blumenfeld (Marta) [born 1955, Ph.D. Biochemistry, ex-Genset] Sc.Dir.-CSO: Gauthier (Jean-Michel) [Ph.D. Molecular Biology, ex-Hybrigenics, Servier, Glaxo Wellcome, INRA] Fin.Dir.-CFO: Faure (Catherine) [Sup de Co Paris, ex-Genset] BusDev: Financers (Hist.): privately owned (private investors) | 3.6 | 2.6 | Cancers | Preclin |
| Aptys Pharmaceuticals Profile + www.aptys-pharmaceuticals.com | 2002 | Centre Clermont-Ferrand | Contract, Research (also, Delivery, Drugs) Key words: Formulation, Peptides, ADHAPT, Bi-Gel, Generic Plus, Insulin delivery Mission: to develop formulation of new chemical entities and peptides/proteins, reformulation of registered molecules and novel drug delivery systems for third parties, to develop internal research programs for own technological portfolio, based on subcontractor cash flow Clients: Pharmaceutical industry, Biotechs Age: 7 year(s) | Spin-off | Managing Dir.-CEO: Boutignon (François) [co-founder, born 1960, Ph.D. protein biochemistry, ex-Europeptides] Sc.Dir.-CSO: Boutignon (François) Fin.Dir.-CFO: BusDev: Financers (Hist.): Sofimac Partners, Crédit Agricole Centre France, privately owned (registered capital 2007 = 0.10 M€) | 0.5 | 0.5 | Multiple | Preclin |
| Ariana Pharmaceuticals Profile + www.arianapharma.com | 2003 | IDF Paris | Contract, Knowledge Key words: Discovery acceleration, Virtual screening, Knowledge management, Decision support, KEM, eADMET, Bioassays Mission: to provide decision-support tools, in order to accelerate drug discovery of third parties Clients: Pharmaceutical industry, Biotechs Age: 6 year(s) | Spin-off | Managing Dir.-CEO: Afshar (Mohammad) [co-founder, born 1966, Ph.D. biochemistry, ex-RiboTargets] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned, Institut Pasteur, Vizille Capital Innovation | 1.5 | 1.5 | Data | Subcontractor |
| Aterovax Profile + www.aterovax.com | 2006 | IDF Paris | Development, Diagnostics Key words: Tests, Atherosclerosis, sPLA2 Activity Test Mission: to develop innovative solutions to predict, diagnose, prevent and treat cardiovascular diseases through a proprietary understanding of atherosclerosis Clients: undisclosed Age: 3 year(s) | Start-up | Managing Dir.-CEO: Surun (Dominique) [born 1958, M.D., CPA, ex-Meda Pharma, Janssen Cilag, 3M] Sc.Dir.-CSO: Valentin (Emmanuel) [Ph.D.] Fin.Dir.-CFO: Regul.Dir.: Doceur (Paula) [Ph.D.] BusDev: Financers (Hist.): SGAM (registered capital 2008 = 0.123 M€) | 3.0 | 3.0 | Cardiovasc | Proof-of-Concept |
| Atlantic Bone Screen Profile + www.atlantic-bone-screen.com | 2005 | Bretagne Nantes | Contract, Services Key words: Validation, In-vivo testing, Osteo-articular pathologies, LPRO Mission: to offer in vitro and in vivo (patented animal models) services dedicated to validation of proof of concept in osteoarticular pathologies, and (Atlanchim) to act as a subcontractor for the synthesis of new molecules Clients: Pharmaceutical industry, Biotechs, Chemical industry, Food industry Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Le Bot (Ronan) [co-founder, born 1977, Pharm.D.] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€), internal growth (no outside investors searched) | n.a. | n.a. | Inflammation | Subcontractor |
| Aureus Pharma Profile + www.aureus-pharma.com | 2000 | IDF Paris | Contract, Knowledge Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE, AurPROFILE Mission: to provide knowledge management solutions to accelerate life science discovery for third parties Clients: Pharmaceutical industry, Biotechs Age: 10 year(s) | Start-up | Managing Dir.-CEO: Theodosiou (Jason) [born 1959, Ph.D. organic chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier Sc.Dir.-CSO: Petitet (François) [Pharm.D., Ph.D.] Fin.Dir.-CFO: Riot-Lamotte (Laurence) BusDev: Financers (Hist.): Bioam, AXA, FCJE (CDC), Matignon, OTC-AM | n.a. | n.a. | Data | Subcontractor |
| B Cell Design Profile + www.b-cell-design.com | 2008 | Centre Limoges | Discover, Drugs Key words: Humanised antibodies Mission: to develop, manufacture humanised IgA and IgG antibodies from genetically modified mice Clients: Clinical labs, Research labs, Medical imaging, Therapists Age: 2 year(s) | Personal venture | Managing Dir.-CEO: Sainte-Laudy (Jean) [born 1946, Ph.D. immunology, ex-Pasteur Cerba] Sc.Dir.-CSO: Cuvillier (Armelle) Techn.Dir.-CTO: Champier (Gaël) Fin.Dir.-CFO: BusDev: Financers (Hist.): Limousin Participation, Limousin Expansion, Limousin Business Angels | 0.1 | 0.1 | Cancers | Proof-of-Concept |
| BioAlliance Pharma Profile + www.bioalliancepharma.com | 1997 | IDF Paris | Discovery, Drugs (also Delivery, Drugs) Key words: Cancer, HIV, Opportunistic infections Mission: to discover, develop and market innovative treatments rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections- with NCE's ans drug delivery improvements Clients: Prescribers Age: 13 year(s) | Start-up | Managing Dir.-CEO: Costantini (Dominique) [co-founder, born 1955, M.D., ex-Hoechst-Marion-Roussel] Oper.Dir.: Avenard (Gilles) [co-founder, born 1951, M.D., ex-Hoechst-Marion-Roussel, CNTS] Sc.Dir.-CSO: Auclair (Christian) [Pharm.D., Ph.D., University Prof.] Fin.Dir.-CFO: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young] SalesMktg: Dupré (Florence) BusDev: Financers (Hist.): 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, AGF P.E., Public | 91.0 | 40.0 | Cancers | Launch |
| Biocortech Profile + www.biocortech.com | 2001 | IDF Paris | Discovery, Drugs Key words: Neuro-psychiatric diseases, Biomarkers, Serotonin, Glutamate Mission: to develop novel biomarkers and treatments for psychiatric disorders, including depression, bipolar disorders, schizophrenia, and cognitive deficits Clients: Pharmaceutical industry (own development, up to clinical trials) Age: 8 year(s) | Spin-off | Managing Dir.-CEO: Weissmann-Pujol (Dinah) [co-founder, born 1951, Pharm.D., Ph.D. neurobiology, ex-Roussel Uclaf, CNRS] Sc.Dir.-CSO: Pujol (Jean-François) [co-founder, M.D., Ph.D., Hospital Professor, ex-Roussel Uclaf, INSERM and CNRS] Fin.Dir.-CFO: BusDev: Financers (Hist.): Institut Pasteur, business angels Communication: website not available (April 2009) | n.a. | n.a. | CNS | Preclin |
| BioCydex Profile + www.biocydex.com | 2002 | Aquitaine Poitiers | Delivery, Drugs (also, Contract, Services) Key words: Ophthalmology, Cyclodextrins Mission: to develop new compound formulations in ophthalmology, cancerology, and organ preservation during transplantation Clients: Pharmaceutical industry (up to clinical stage) Age: 7 year(s) | Personal venture | Managing Dir.-CEO: Belgsir (El Mustapha) [co-founder, born 1958, Ph.D., ex-CNRS] Sc.Dir.-CSO: Cenatiempo (Yves) [co-founder, also board chairman, born 1950, Prof. biochemistry (Poitiers)] Fin.Dir.-CFO: Marembaud (Olivier) [born 1952, ex-Frantour, Kelois, SNCF] BusDev: Financers (Hist.): Oseo | n.a. | n.a. | Ophthamo | Preclin |
| BioMedical Diagnostics Profile + www.bmd-net.com | 1986 | IDF Marne-la-Vallée (near Paris) | Discovery, Diagnostics (also, Design, Devices) Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases Clients: Pharmaceutical industry Age: 24 year(s) | Start-up | Managing Dir.-CEO: Magrez (Paul) [born 1958, M.D., Ph.D. computer science (Bruxelles), ex-GSK, UCB, Innogenetics] Sc.Dir.-CSO: Fin.Dir.-CFO: Géricot (Laurence) [MBA, ex-Hewlett Packard] BusDev: Financers (Hist.): Truffle Venture, CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova | n.a. | 3.0 | Allergy | Trade |
| Biométhodes Profile + www.biomethodes.com | 1997 | IDF Évry (near Paris) | Contract, Manufacturing (also Design, Drugs) Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme Mission: to provide third parties with industrial processes based on proprietary know-how on improved enzymes, and to develop a next generation biologicals, with an initial focus on haemophilia, from sister company platform, Biométhodes Therapeutics Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food Age: 12 year(s) | Personal venture | Managing Dir.-CEO: Amsallem (Gilles) [born 1954, ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio] Sc.Dir.-CSO: Delcourt (Marc) [founder, born 1970, M.D., Normale Sup] Fin.Dir.-CFO: Liju (Xavier) BusDev: Financers (Hist.): CDC Innovation, CIC Capital, FCJE (CDC) | n.a. | n.a. | Haemophilia | Trade |
| Biom'up Profile + www.biomup.com | 2005 | Rhône-Alpes Saint-Priest (near Lyon) | Development, Biomaterials & Medical devices (also, Contract, Manufacturing) Key words: Devices, Collagen, Glycosaminoglycans, Biopolymers, Grafting, Human reconstruction Mission: to develop and manufacture innovative biopolymers, such as collagens, for implantable Medical Devices, with a special focus on long term applications, and to design customized Purification Tools, particularly in affinity chromatography Clients: Pharmaceutical industry, Cosmetic industry, Biotechs Age: 5 year(s) | Spin-off | Managing Dir.-CEO: Picot (Sylvain) [co-founder, born 1978, Ph.D., Insa], Sc.Dir.-CSO: Forest (Patricia) [co-founder, born 1978, Ph.D., Insa], also COO] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned | 0.04 | 0.04 | Collagen | Trade |
| BioProtein Technologies Profile + www.bioprotein.com | 1998 | IDF Jouy-en-Josas (near Paris) | Contract, Manufacturing Key words: Therapeutic proteins, Gene expression, Transgenic rabbits Mission: to provide third parties with production of recombinant therapeutic proteins and vaccines in the milk of transgenic rabbits, as a fully integrated service from gene expression to industrial production of purified proteins and vaccines Clients: Pharma industry, Research labs, Biotechs Age: 11 year(s) | Personal venture | Managing Dir.-CEO: Lignel (Jean) Sc.Dir.-CSO: Ripoll (Pierre-Jean) [Ph.D., ex-Aventis, Biogemma] Fin.Dir.-CFO: BusDev: Fouassier (Alexandre) [Eng. INRA, M.Sc. biochemistry, also COO] Financers (Hist.): Société Générale A.M., Gilde, Creagro, Iwic, Anvar | 9.5 | 1.5 | Multiple | Preclin |
| BioQuanta Profile + www.bioquanta.com | 2003 | IDF Paris | Contract, Research (also, Discovery, Drugs) Key words: Angiogenic drug, In Silico subcontractor, Bio-informatics, MultiDIP Mission: to offer in silico services and biological services for the selection and improvement of third parties' potentially therapeutic compounds, by predicting their toxicity, bioavalability ADME and profile Clients: Biotech companies, Pharmaceutical, Food and Cosmetics industries Age: 7 year(s) | Personal venture | Managing Dir.-CEO: Mauclaire (Jean-Michel) [born 1957, co-founder, Sup de Co (Paris), CPA Accounting, ex-Lindsey, Lafarge] Sc.Dir.-CSO: Fin.Dir.-CFO: Cottin (Jean-Matthieu) [Sup de Co (Paris), ex-Eli Lilly, Nutricia] BusDev: Boudières (Daniel) Financers (Hist.): privately-owned (undisclosed private investors) | 0.05 | 0.05 | Cancers | Patents |
| BioSystems International Profile + www.biosys-intl.com | 2004 | IDF Évry (near Paris) | Design, Diagnostics Key words: Biomarkers, Drug discovery improvement, Development productivity, Serum proteins Mission: to discover and validate biomarkers through partnerships with pharmaceutical, biotechnology and diagnostics companies and in-house research programs or academic collaborations Clients: Pharmaceutical industry (AstraZeneca), Biotechs Age: 5 year(s) | Spin-off | Managing Dir.-CEO: Tirouflet (Jean-Pierre) [born 1950, ENA, ex-Rhodia (President), MEDEF, Rhône-Poulenc, Finance Ministry, Crédit National Bank Sc.Dir.-CSO: Takacs (Laszlo) [co-founder, born 1955, M.D., Ph.D., ex-Pfizer, Parke Davis, Amgen, NIH] Tech.Dir.-CTO: Guttman (András) [co-founder, Ph.D. Chemistry, ex-Beckman Coulter] Fin.Dir.-CFO: Hollai (Andrea) [MBA, ex-Hungarian Journalist’s Federation] BusDev: Financers (Hist.): Société Générale Note : a susidiary (research) in Hungary | 6.5 | 3.5 | Multiple | Trade |
| BMSystems (Bio-Modeling) Profile + www.bmsystems.net | 2004 | IDF Paris | Discovery, Hub Key words: Models, Proof of concept, Predictive efficacy, Validation, Spin-off Mission: to help clients run their life sciences R&D programs better, faster, cheaper and safer by applying CADI methodologies and tools, an operational systems biology approach Clients: R&D departments (on a partnering basis), Financers (in case of spin-off) Age: 5 year(s) | Start-up | Managing Dir.-CEO: Géa (Manuel) [co-founder, born 1960, Eng. Centrale, ex-Hemispherx (CEO), Boehringer-Ingelheim, Colgate-Palmolive, McKinsey] Sc.Dir.-CSO: Iris (François) [also board chairman, born 1950, Ph.D., ex-Valigen (co-founder), Millenium] Med.Dir.-CMO: Dine (Gérard) [M.D., Ph.D.] I.T.Dir.-CIO: Santamaria (Pablo) [Eng. Centrale, ex-Formitel, Glaxo] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately-owned (no search for external investors) | n.a. | n.a. | Multiple | Proof-of-Concept |
| BT Pharma Profile + www.btpharma.com | 2001 | Midi-Pyrénées Labège (near Toulouse) | Discovery, Immunology Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections, ProCervix Mission: to develop immuno-therapeutic products for the treatment of infection, neoplasia and cervical cancer, caused by Human Papillomavirus (HPV) Clients: Prescribers Age: 8 year(s) | Spin-off | Managing Dir.-CEO: Timmerman (Ben) [founder, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia] Sc.Dir.-CSO: Préville (Xavier) [Ph.D. Life Sciences, Gercor, Sangstat] Fin.Dir.-CFO: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon] BusDev: Financers (Hist.): Institut Pasteur, FAM-Midi-Pyrénées, Edmond de Rothschild Investment Partners | 9.0 | 2.8 | Vaccines | Preclin |
| Carmat Profile + www.carmatsas.com | 2008 | IDF Vélizy (near Paris) | Development, Device Key words: Artificial heart, Computer simulation, Electronic captors, Bioprothesis Mission: to clinically develop, then market a fully implantable artificial heart for patients suffering in the aftermath of a massive heart attack or with late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible Clients: Hospitals Age: 1 year(s) | Spin-off | Managing Dir.-CEO: Conviti (Marcello) [Ph.D., MBA, ex-Edwards Lifesciences, Sorin] Sc.Dir.-CSO: Carpentier (Alain) [born 1933, co-founder, M.D. (surgery), Hospital Professor] Fin.Dir.-CFO: BusDev: Financers (Hist.): Truffle Capital, Oseo, EADS Note : company first sourced as a J.V. Carpentier-Matra, in 1993 (company name, Carmat = Carpentier + Matra) Note : Internet showroom, available since June 2009 | 7.5 | 7.5 | Cardiovasc | Preclin |
| Cellectis Profile + www.cellectis.com | 2000 | IDF Romainville (near Paris) | Discovery, Therapy (also Research, Subcontractor) Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.) Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs Competitors: Applied Biosystems, 454 Life Sciences, Celera Age: 10 year(s) | Spin-off | Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology] Sc.Dir.-CSO: Pâques (Frédéric) [Ph.D. Sciences, Normale Sup (Ulm), ex-CNRS] Fin.Dir.-CFO: Le Bozec (Marc) [HEC, ex-Alfact Innovation, Arthur D. Little, BioProtein (founder)] BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO] BusOff.: Dick Pollet [ex-Galapagos] Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics] Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis] Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, Public | 60.6 | 22.0 | Genome | Preclin |
| Cellial Technologies Profile + www.cellial.com | 2001 | North-Picardie Lens | Contract, Research Key words: CNS research optimization, In vitro cell culture, Blood-Brain Barrier Mission: accelerate CNS profiling and identify qualified leads candidates and eliminates the botleneck of drug transport accross Blood-Brain Barrier from clients' discovery process Clients: Pharmaceutical industry, Biotechs, Academic labs Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Leman (Sandrine) [born 1971, Ph.D., Institut Pasteur] Sc.Dir.-CSO: Berezowski (Vincent) [Ph.D.] Fin.Dir.-CFO: BusDev: Financers (Hist.): Finorpa, Nord Innovation, Innovam Communication: no website news update since 2005 in October 2008 | 1.0 | 1.0 | Multiple | Subcontractor |
| CellProthera Profile + www.cellprothera.com | 2008 | Alsace Mulhouse | Discovery, Devices Key words: Cell Therapy, Regeneration, Myocardial tissue Mission: to develop innovative stem cell therapy for the regeneration of myocardial tissue, allowing prevention of chronic heart failure after myocardial infarction Clients: not disclosed Age: 1 year(s) | Personal Venture | Managing Dir.-CEO: Lataste (Xavier) [Ph.D. clinical neurochemistry, M.D., ex-Sandoz, Novartis] Sc.Dir.-CSO: Hénon (Philippe) [founder, born 1938, M.D. Hematology, IRHT (founder, 1987), University Prof., also Board Chairman] Oper.Dir.-COO: Jelsch (Jean-Claude) [CNAM, MBA (CPA, Lyon), ex-Ecco, Adecco] Med.Dir.-CMO : Lataste (Xavier) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned, Financière Bendelé, Alsace Business Angels (registered capital 2008 = 0.05 M€) | 1.6 | n.a. | Cardiovasc | Proof-of-Concept |
| CellVax Profile + www.cellvax-pharma.com | 2001 | IDF Évry (near Paris) | Contract, Services Key words: Preclinical validation studies, Cancer, Viral diseases, Nodule, Angiogenesis model Mission: to provide third parties with complete preclinical innovating services allowing to accelerate the drug development process in oncology field Clients: Pharmaceutical industry, Biotechs, Public-sector labs (up to phase II) Age: 8 year(s) | Personal venture | Managing Dir.-CEO: Wei (Ming) [co-founder, born 1963, Ph.D. molecular biology] Sc.Dir.-CSO: Wei (Ming) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) Note : webhosting with Lycos withdrawn in March 2009 | n.a. | n.a. | Cancers | Subcontractor |
| CellVir Profile + www.cellvir.com | 2006 | IDF Évry (near Paris) | Discovery, Drugs Key words: Anti-retrovirals, AIDS, HCV, SARS, Avian Flu Mission: to develop a new generation of anti-retrovirals by targeting the host-virus protein-protein interactions Clients: Pharmaceutical industry (own clinical development up to phase IIa) Age: 3 year(s) | Personal venture | Managing Dir.-CEO: Courtney (Michael) [Scottish, Ph.D., ex-Aptanomics, Noxxon, Trangene (CSO)] Sc.Dir.-CSO: Benarous (Richard) [co-founder, born 1941, M.D., Ph.D., ex-Hybrigenics (co-founder), Cytomics (co-founder)] Fin.Dir.-CFO: BusDev: Financers (Hist.): OSEO, ANRS, ANR, Genopole 1er Jour and INSERM Transfert Note (February 2010) : the company web site Internet is unavailable and the URL does not exist any more (temporarily ?) | 2.0 | 2.0 | Virus | Incub |
| Cerenis Therapeutics Profile + www.cerenis.com | 2004 | Midi-Pyrénées Labège (near Toulouse) | Discovery, Drugs Key words: HDL therapy, Cholesterol, Atherosclerosis, Cardiovasculars Mission: to discover, develop and market next generation HDL therapies Clients: Prescribers Age: 5 year(s) | Personal venture | Managing Dir.-CEO: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier] Oper.Dir.-COO: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo] Sc.Dir.-CSO: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer] Fin.Dir.-CFO: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers] Med.Dir.-CMO: Scott (Rob) [M.D., ex-AtheroGenics, Pfizer] BusDev: Brya (Tom) [MBA (Northwestern), MST, CPA, ex-Pharmacia, Monsanto/Searle, Cardinal Health, KV Pharmaceutical] Financers (Hist.): Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures | 67.0 | 42.0 | Cardiovasc | Clinical |
| Cezanne Profile + www.cezanne.fr | 2000 | Méditerranée Nîmes | Development, Devices Key words: Immunochemistry analysis, Kryptor analyser, Fluorescence detection, Trace technology, Automatic instruments, Reagents Mission: to develop innovating diagnostics products, notably the the Kryptor system, a software and fluorescence reading system (supplied as an OEM component for Pharma research groups) Clients: Pharma industry, R&D labs Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Bois (Emmanuel) [co-founder, born 1960] Sc.Dir.-CSO: Bois (Emmanuel) Fin.Dir.-CFO: BusDev: Financers (Hist.): | n.a. | n.a. | Multiple | Trade |
| CliniGenetics Profile + www.clinigenetics.com | 2000 | Méditerranée Nîmes | Discovery, Drugs Key words: Atherothrombosis, Atherix pig model, Alive bio-informatics Mission: to discover new therapeutics for the treatment of cardiovascular, cerebrovascular and lower limb ischemic diseases with a specific emphasis on atherothrombosis Clients: Prescribers Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Falco (Jean-Louis) [born 1949, also board chairman, DEA Mkg-Finance Dauphine, ex-Schneider, Aurex (own consulting company)] Sc.Dir.-CSO: Marguerie de Rotrou (Gérard) [born 1940, Ph.D., ex-Inserm, CEA, University Professor in Functional Genomics] Fin.Dir.-CFO: BusDev: Financers (Hist.): BankInvest Note (February 2010) : the company web site Internet is unavailable and the URL does not exist any more (temporarily ?), no legal process since 2007 | n.a. | n.a. | Cardiovasc | Preclin |
| Covalab Profile + www.covalab.com | 1995 | Rhône-Alpes Villeurbanne (near Lyon) | Design, Drugs (also Design, Diagnostics) Key words: Immunochemistry, MABs, Polyclonal antibodies Mission: to supply innovative and unique polyclonal and monoclonal antibodies to third parties, such as universities, research institutes and commercial organisations around the world Clients: Research labs Age: 14 year(s) | Personal venture | Managing Dir.-CEO: El Alaoui (Saïd) [born 1955] & Thomas (Vincent) [born 1957] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2007 = 0.24 M€) Communication: no website corporate news since 2005 | n.a. | n.a. | Multiple | Trade |
| Cytheris Profile + www.cytheris.com | 1999 | IDF Issy-les-Moulineaux (near Paris) | Discovery, Immunology Key words: Immune modulation, Cancer, HIV, HCV, Recombinant interleukin Mission: to discover and develop new therapies for immune modulation, by reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT) Clients: Prescribers Age: 11 year(s) | Personal venture | Managing Dir.-CEO: Morre (Michel) [founder, born 1946, Vet.D., ex-Sanofi-Aventis, Pierre Fabre, M.I.T.] Sc.Dir.-CSO: Fin.Dir.-CFO: Vannier (Bertrand) BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma] Financers (Hist.): Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion (registered capital 2006 = 52.5 M€) | 31.3 | 24.3 | Cancers | Clinical |
| Cytomics Profile + www.cytomics.fr | 2000 | IDF Orsay (near Paris) | Discovery, Drugs Key words: Ubiquitin ligases, UbiScreen, High-throughput Screening, Cancer, Nosocomial Fungal Infections Mission: to discover and develop small molecules controlling protein turnover, to treat serious human diseases, notably inflammatory diseases and cancer and nosocomial fungal infections Clients: Prescribers Age: 9 year(s) | Start-up | Managing Dir.-CEO: Cambou (Bernard) [born 1955, MBA (Essec), ex-StageMark (co-founder), Aventis-Principia, HGS, MIT] Sc.Dir.-CSO: Hercend (Thierry) [born 1952, oncologist, also Supervisory Board President, Cytomics, BT Pharma] Fin.Dir.-CFO: Martin (Erwan) [Sup de Co (Toulouse), MBA, ex-Syndex] BusDev: Financers (Hist.): Société Générale A.M., Edmond de Rotschild I.P., Truffle Venture | 13.0 | 10.0 | Cancers | Preclin |
| Cytoo Profile + www.cytoo.com | 2008 | Rhône-Alpes Grenoble | Contract, Research Key words: Adhesive micropatterns, High Content Analysis, Cell based assays, Cell Screening Mission: to develop, manufacture, and distribute products that make cellular analysis robust and reliable by drastically decreasing cell variability Clients: Pharmaceutical industry Age: 1 year(s) | Personal venture | Managing Dir.-CEO: Chatelain (François) [co-founder, ex-CEA, Protogene, Life Technologies, Genset, DNAgency] Sc.Dir.-CSO: Bornens (Michel) [co-founder, board member, ex-Pasteur Institute, Curie Institute] Oper.Dir.-COO: Fuchs (Alexandra) [co-founder, Ph.D. biochemistry, Eng. Centrale, ex-CEA] Fin.Dir.-CFO: BusDev: Sharp (William) [also President-CEO Cytoo Inc.] Financers (Hist.): privately owned (registered capital 2008 = 0.1 M€), Auriga Partners, CEA Valorisation, Rhône-Alpes-Création, Expansinvest, (undisclosed) private investors | 4.2 | 3.2 | Consumables | Trade |
| DBV Technologies Profile + www.dbv-technologies.com | 2002 | IDF Boulogne Billancourt (near Paris) | Discovery, Diagnostics Key words: Allergies, Electrostatic patch, Diallertest, Viaskin Mission: to develop Viaskin, an innovative non invasive delivery technology, suitable for severe allergic patients to food allergy both in diagnosis and specific immunotherapy treatment Clients: Pharmaceutical industry, Food industry, Cosmetics Age: 7 year(s) | Start-up (speciality pharma company) | Managing Dir.-CEO: Biry (Jean-François) [born 1955, ex-Cider Santé (President)] Sc.Dir.-CSO: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics] & Dupont (Bertrand) [Ensam] Fin.Dir.-CFO: BusDev: Financers (Hist.): Cap Décisif, Créagro, Sofinnova Partners, Apax Partners, Sofinnova Partners, ALK-Abello (Pharma company) | 19.3 | 6.0 | Allergy | Trade |
| DNA Therapeutics Profile + www.dna-therapeutics.com | 2006 | IDF Évry (near Paris) | Discovery, Drugs Key words: Cancer, siDNA, DNA repair Mission: to develop proprietary siDNA (signal interfering DNA) technology platform and molecules, interfering with DNA damage repair mechanisms, to fight treatment-resistant cancers Clients: Prescribers Age: 3 year(s) | Personal venture | Managing Dir.-CEO: Sun (Jian Sheg) [born 1959, also board chairman, Ph.D.] Sc.Dir.-CSO: Sun (Jian Sheg) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned | 3.4 | 2.2 | Cancers | Preclin |
| Domain Therapeutics Profile + www.domaintherapeutics.com | 2001 | Alsace Illkirch Graffenstaden (near Strasbourg) | Discovery, Drugs Key words: Neurological disorders, Neurotransmitter modulation, GPCR, Neuroclide, Glutamate inhibitor, Utrophin inducer Mission: to discover and develop new treatments notably (but not only) for neurological disorders, with a focus on GPCR-mediated neurotransmitter modulation Clients: Prescribers (own development up to phase III) Age: 8 year(s) | Personal venture | Managing Dir.-CEO: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor] Sc.Dir.-CSO: Neuville (Pascal) & Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo] Fin.Dir.-CFO: BusDev: Financers (Hist.): Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE, Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly Communication: the company was named Faust Pharmaceuticals from inception till December 2008, with URL as www.faustpharma.com | 29.3 | 2.1 | CNS | Clinical |
| Dynabio Profile + www.dynabio.com | 1992 | Méditerranée Marseille | Design, Diagnostics Key words: Stress proteins, Pancreatitis-Associated Protein (PAP), PancrePAP kit Mission: to develop new immunological tools to improve detection of Pancreatitis-Associated Protein (PAP), as a new class of stress proteins whose expression reflects with extreme sensitivity pathological alterations of several tissues in the gastrointestinal tract Clients: Research labs Age: 17 year(s) | Personal venture | Managing Dir.-CEO: Broto (Ruben) [born 1937] Sc.Dir.-CSO: Oper.Dir.: Slagel (Dean) [born 1970] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned Communication: no website news update since 2006, extremely limited media information since inception | n.a. | n.a. | Multiple | Preclin |
| EchoSens Profile + www.echosens.com | 2001 | IDF Paris | Discovery, Devices Key words: Obesity, Hepatitis C, Hepatitis B, Fibroscan Mission: to develop, manufacture and market new diagnostic devices in the field of hepatology (FibroScan being the first and only non-invasive device for diagnosis and monitoring of hepatic fibrosis) Clients: Hospitals (through distributors and subsidiaries) Age: 8 year(s) | Start-up | Managing Dir.-CEO: Guillaume (Richard) [born 1955, ex-Blatchford, Abbott, Mead Johnson] Sc.Dir.-CSO: Sandrin (Laurent) [co-founder, ESCPI, Ph.D. physics, ex-LOA] Fin.Dir.-CFO: BusDev: Financers (Hist.): OTC Asset Management, Cap Décisif | n.a. | n.a. | Liver | Clinical |
| Edelris Profile + www.edelris.com | 2005 | Rhône-Alpes Lyon | Contract, Research Key words: Screening, Medicinal chemistry, Small molecules, Mimetics, CombiChem Mission: to design and produce innovative, therapeutically relevant, natural-mimetic screening compounds, in order to accelerate the hit-lead discovery process in pharmaceutical and biotech research organizations Clients: Pharmaceutical industry Age: 5 year(s) | Spin-off | Managing Dir.-CEO: Ortholand (Jean-Yves) [co-founder, born 1965, Ph.D., ex-Bayer, Rhône Poulenc Santé, Merck Santé] Sc.Dir.-CSO: Greiner (Alfred) [co-founder, Ph.D., ex-Rhône Poulenc] Fin.Dir.-CFO: BusDev: Financers (Hist.): | n.a. | n.a. | Multiple | Subcontractor |
| Endotis Pharma Profile + www.endotis.com | 2003 | IDF Romainville (near Paris) | Discovery, Drugs Key words: Small-glyco drugs (SGD), Thrombosis, Cancer Mission: to discover and develop Small-glyco drugs (SGD) for application in thrombosis and oncology Clients: Prescribers Age: 7 year(s) | Start-up | Managing Dir.-CEO: Woller (Charles) [born 1949, M.D., Ph.D. Clinical pharmacology, MBA, ex-Neuro3D (founder), Cadus, Roche France (Managing Director), Warner Lambert, Akzo] Sc.Dir.-CSO: Petitou (Maurice) [Ph.D., ex-Sanofi, Lauréat Prix Charles Mentzer 2009] Fin.Dir.-CFO: Degove (Stéphane) [Sup de Co (Paris), ex-Sanofi, Orica, OC&C] BusDev: Financers (Hist.): Endeavour Vision, NIF SMBC Ventures, Sofinnova Partners | 34.0 | 25.0 | Multiple | Preclin |
| Epixis Profile + www.epixis.com | 2003 | IDF Paris | Discovery, Immunology Key words: Flu, C-Hepatitis, Mimetic particles, Virus-like particle vaccines Mission: to develop a platform technology for a new generation of Virus-Like Particle vaccines (eVLP) that may allow to quickly manufacture seasonal or pandemic flu vaccines, to treat Hepatitis C, and to be applied to other infectious diseases, such as HPV or HIV Clients: Pharmaceutical industry Age: 6 year(s) | Personal venture | Managing Dir.-CEO: Dalba (Maria) [born 1967, M.D., Ph.D.] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Génopole 1er Jour | n.a. | n.a. | Virus | Preclin |
| ERYtech Pharma Profile + www.erytech.com | 2004 | Rhône-Alpes Lyon | Delivery, Drugs Key words: Encapsulation, Red blood cells, Cancer, Cleav'Ery, Oxygen'Ery, Deliv'Ery, Vaccin'Ery, Graspa Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients Clients: Prescribers Age: 5 year(s) | Personal venture | Managing Dir.-CEO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed] Oper.Dir.: Goineau (Pierre-Olivier) [co-founder, born 1967, ex-KPMG] Sc.Dir.-CSO: Godfrain (Yann) Med.Dir.: Liens (David) [M.D., ex-Merck (KgaA) Fin.Dir.-CFO: Dujardin (Philippe) [Ms. finance, ex-Atari, Suez-Lyonnaise des Eaux] BusDev: Bouvier (Maud) [Sup de Co (Grenoble)] Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys | 13.0 | 12.0 | Cancers | Clinical |
| Exonhit Profile + www.exonhit.com | 1997 | IDF Paris | Discovery, Diagnostics (also, Discovery, Drugs) Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer Mission: to leverage on alternative RNA splicing, the process by which a single gene can lead to several proteins in the fields of drug discovery, diagnostics and biochips and to sell proprietary gene profiling technology named Datas in order to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease Clients: Pharmaceutical industry (own development up to phase II) Age: 12 year(s) | Personal venture | Managing Dir.-CEO: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhône Poulenc Rorer] Sc.Dir.-CSO: Pando (Matthew) [Ph.D.] and Jaskowiak (John R.) [ex-Hewlett Packard, Agilent, Affymetrix] Fin.Dir.-CFO: Duchesne de Lamotte (Hervé) [MBA, Ms (MIT), ex-Stanford Research Institute, AT Kearney France, IDM, Cirrus Finance Management] BusDev: Vickery (William) [MBA, ex-Roche Pharma] Comm.Dir.: Hoff (Corinne) [ex-Nicox, Aventis, Novartis)] Financers (Hist.): CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Biomérieux (5.8%, end 2007), Public | 101.1 | 15.6 | Genome | Clinical |
| Eye Tech Care Profile + www.eyetechcare.com | 2008 | Rhône-Alpes Rillieux la Pape (near Lyon) | Development, Devices Key words: Ultra-sounds, Ophthalmology Mission: to develop a proprietary ultrasound-based procedure for treating eye diseases Clients: undisclosed Age: 1 year(s) | Personal venture | Managing Dir.-CEO: Romano (Fabrizio) [co-founder, born 1962, Vet.D., ex-Edap TMS] Clin.Dir.: Farcy (Laurent) [co-founder, born 1973, Ms. biochemistry, ex-Medicrea, Sofradim] Indus.Dir.: Chapuis (Philippe) [co-founder, born 1968, Eng. ESEM Orléans, IAE, ex-Edap TMS] Fin.Dir.-CFO: BusDev: Financers (Hist.): Crédit Agricole, CEA Valorisation | 0.6 | 0.6 | Ophtalmology | Preclin |
| Flamel Technologies Profile + www.flamel.com | 1990 | Rhône-Alpes Venissieux (near Lyon) | Delivery, Drugs (also, Design, Devices) Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action Mission: to improve the therapeutic characteristics, safety profile and ease of use of a wide variety of existing drugs, by using proprietary drug delivery platforms, Medusa for therapeutic proteins and peptides and Micropump for small molecules, with expertise in polymer chemistry Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry Age: 19 year(s) | Start-up | Managing Dir.-CEO: Willard (Stephen H.) [born 1960, ex-Biovail, Crédit Suisse, Gibson-Dunn-Crutch, Shearman & Sterling] Sc.Dir.-CSO: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé] Oper.Dir.-COO: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé] Fin.Dir.-CFO: Crouzet (Sian) [ex-McCormik, Ernst & Young] BusDev: Franoux (Grégoire) Strat.Dir.: Marlio (Charles) [ex-Baldwin Brothers] Financers (Hist.): Public (Nasdaq) | n.a. | n.a. | Multiple | Trade |
| Fluofarma Profile + www.fluofarma.com | 2003 | Aquitaine Bordeaux | Contract, Research (also, Contract, Services) Key words: High Content Screening (HCS), Automated flow cytometry, Cell-based assays Mission: to provide third parties with High Content Screening (in-cellulo screening) services for target and drug discovery, predictive toxicity testing and cosmetics development Clients: Pharmaceutical industry, Biotech, Cosmetic industry Age: 6 year(s) | Spin-off | Managing Dir.-CEO: Pin (Jean-Baptiste) [founder, born 1974, ex-Ernst & Young Biotechnology] Sc.Dir.-CSO: Depierre (Gaëlle) [ex-Urogene] Fin.Dir.-CFO: BusDev: Mahfoudi (Abderrahim) [ex-Aventis, Nautilus Biotech, Intergragen, Cerep, Guerbet, Inserm-Transfert] Financers (Hist.): privately owned (registered capital 2006 = 0.24 M€) Communication: only events and scientific publications, mentioned in Web site | n.a. | n.a. | Multiple | Subcontractor |
| GemacBio Profile + www.gemacbio.com | 1999 | Aquitaine Berganton, Saint Jean d’Illac (near Bordeaux) | Development, Diagnostics (also, Contract, Manufacturing) Key words: Antibodies, Customization, CNS disorders, Auto-immune diseases Mission: to develop a wide range of monoclonal and polyclonal antibodies against neurotransmitters, nitrosylated and nitrated amino-acids, bacterial antigens Clients: Distributors, Pharmaceutical industry, Biotech, Research labs Age: 10 year(s) | Personal venture | Managing Dir.-CEO: Lurton (Louis) [born 1956] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): IRDI, ACI, SOCRI, Oséo/Anvar, business angels | n.a. | n.a. | CNS | Trade |
| Genepep Profile + www.genepep.com | 2003 | Midi-Pyrénées Prades le Lez (near Montpellier) | Contract, Research (also, Discovery, Drugs) Key words: Peptides, Transcriptomes, Bio-informatics softwares Mission: to provide third parties with custom peptide synthesis, antibody production, peptide and protein sequencing, mass spectrometry, and to design own peptides for therapeutic research Clients: Pharmaceutical industry (own development up to proof of concept) Age: 7 year(s) | Personal venture | Managing Dir.-CEO: Puget (Karine) [co-founder, born 1970, Ph.D., ex-CNRS] Sc.Dir.-CSO: Bulet (Philippe) [ex-CNRS, Entomed, Funzyme] Fin.Dir.-CFO: BusDev: Financers (Hist.): Sud Angels | n.a. | n.a. | Multiple | Preclin |
| Genewave Profile + www.genewave.com | 2001 | IDF Palaiseau (near Paris) | Design, Devices Key words: Automated real-time micro-array, Hybridization imaging systems, Low-cost micro-array readers, HybLive Mission: to develop, manufacture and market cutting-edge microarray instrumentation for diagnostic, clinical and life science research Clients: Research labs, Biotech, Other Institutions, OEM markets Age: 8 year(s) | Personal venture | Managing Dir.-CEO: Desforges (François-Xavier) [born 1960, Ph.D. Electronics, ex-Photonetics] Oper.Dir.-COO: Choumane (Houtaï) [Ph.D. Optics, also co-CEO] Sc.Dir.-CSO: Weisbuch (Claude) [co-founder, born 1945, Ph.D. physics, Normale Sup, CNRS, University Professor (USA), ex-Bell Laboratories, Saint-Gobain, Thomson-CSF] and Cerovic (Gordana) [Ph.D., ex-ValiGen] Fin.Dir.-CFO: BusDev: Financers (Hist.): | n.a. | n.a. | Multiple | Trade |
| Genfit Profile + www.genfit.com | 1999 | North-Picardie Lille | Discovery, Drugs Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes Mission: to discover new treatments for major cardiovascular, metabolic and inflammatory diseases, as well as age-linked neurodegenerative disorders Clients: Pharmaceutical industry Age: 10 year(s) | Start-up | Managing Dir.-CEO: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M] Sc.Dir.-CSO: Hum (Dean W.) [Ph.D. biochemistry] Fin.Dir.-CFO: Huitorel (Nathalie) [Sup de Co (Lille), ex-MS Composites, Finuchem] BusDev: Financers (Hist.): Finorpa, Nord Cration, BP Création, Public | n.a. | 2.3 | Cardiovasc | Clinical |
| GenOdyssee Profile + www.genodyssee.com | 1999 | IDF Évry (near Paris) | Discovery, Drugs Key words: Protein optimization, Low-burn model, Interferon, HCV Mission: to discover superior protein products by using a unique, IP-protected approach and a proprietary genomic DNA databank Clients: Prescribers Age: 10 year(s) | Personal venture | Managing Dir.-CEO: Escary (Jean-Louis) [founder, born 1964, Ph.D. molecular biology, ex-UCLA, CNG, ] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Matignon I.F., Edmond de Rotschild Fin., Société Générale A.M., George Cohen | n.a. | n.a. | Virus | Preclin |
| Genomic Vision Profile + www.genomicvision.com | 2004 | IDF Paris | Discovery, Drugs (also, Discovery, Diagnostics) Key words: Diagnostics, Nanotechnology, DNA, Molecular combing Mission: to develop novel diagnostic, biomarkers and drug discovery solutions based on proprietary nanotechnology for DNA analysis in the areas of cancer and acute diseases Clients: Pharmaceutical industry (Sanofi-Aventis), Biotechs Age: 5 year(s) | Personal venture | Managing Dir.-CEO: Bensimon (Aaron) [born 1957, co-founder, Ph.D. molecular biology, ex-Institut Pasteur] Sc.Dir.-CSO: Oper.Dir.-COO: Nerson (Daniel) [born 1958, co-founder, Ph.D., ex-Pasteur Mediavita, Dade-Behring] Fin.Dir.-CFO: BusDev: Financers (Hist.): Société Générale Asset Management Alternative Investments (SGAM AI), Vesalius BioCapital | 6.0 | 4.0 | Multiple | Preclin |
| GenoSafe Profile + www.genosafe.com | 2003 | IDF Évry (near Paris) | Contract, Services Key words: Bio-therapeutics, Drug evaluation Mission: to evaluate the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …), for third parties Clients: Pharmaceutical industry, Biotechs, Research labs Age: 6 year(s) | Start-up | Managing Dir.-CEO: Caizergues (Didier) [born 1958, Pharm.D., ex-Synthelabo, Abbott, Genethon] Sc.Dir.-CSO: Audit (Muriel) [Ph.D. Biology, ex-Genethon] Fin.Dir.-CFO: BusDev: Zuliani (Vincent) [Ms. microbiology, ex-Genethon] Financers (Hist.): A2I (seed), Genethon, AFM | 3.5 | 3.5 | Multiple | Subcontractor |
| GenoScience Pharma Profile + www.genosciencepharma.com | 2001 | Méditerranée Marseille | Discovery, Drugs (also, Contract, Research) Key words: Antivirals, Predict-Search, GenMol, Protease inhibitor, HCV Mission: to develop new drugs for the treatment of viral diseases and the identification of molecular markers to monitor antiviral therapies and to answer the problem of microarray interpretation, by using PredictSearch, a proprietary powerful data mining based software Clients: Pharmaceutical industry Age: 8 year(s) | Personal venture | Managing Dir.-CEO: (interim) Halfon (Philippe) [founder, born 1960, M.D., Ph.D., Alphabio (CEO)] Sc.Dir.-CSO: Benech (Philippe) [Ph.D., ex-CNRS] Fin.Dir.-CFO: Corroy (Jean-Paul) [Sup de Co, ex-Alphabio] BusDev: Financers (Hist.): | n.a. | n.a. | Virus | Preclin |
| Genoscreen Profile + www.genoscreen.fr | 2001 | North-Picardie Lille | Contract, Research Key words: DNA, Genome, Sequencing, Genotyping, Mutation detection, Gene expression, Microbial identification, Microbial typing Mission: to develop and to realize innovative services on all kind of genomes to provide answers that best suit the needs of research laboratories, by using own high throughput equipments Clients: Pharmaceutical industry, Research labs, Life science industries, Academic research institutions Age: 9 year(s) | Spin-off | Managing Dir.-CEO: Tordeux (André) [born 1947] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned | n.a. | n.a. | Genome | Subcontractor |
| GenOway Profile + www.genoway.com | 1999 | Rhône-Alpes Lyon | Contract, Research Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests Mission: to provide third parties with customized and ready-to-use genetically modified mouse and rat models (Knock-out, conditional Knock-out, Knock-in, RNAi, humanized, transgenic mice and rats) Clients: Research labs Age: 11 year(s) | Spin-off | Managing Dir.-CEO: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA] Sc.Dir.-CSO: Fin.Dir.-CFO: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome] BusDev: Thiam (Kader) Financers (Hist.): Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public | 10.8 | 1.1 | Genome | Subcontractor |
| GTP Technology Profile + www.gtptech.com | 2000 | Midi-Pyrénées Labège (near Toulouse) | Contract, Manufacturing (also, Design, Drugs) Key words: In-vitro protein production, Gene work, Eiffel biostructure, L-lactis, Sensorines, Therapeutic protein, Cancers Mission: to provide third parties with taylor-made solutions for the engineering and expression of recombinant proteins, and, to undertake own research on the L.lactis system for therapeutic proteins production Clients: Pharma industry, Biotechs, Research labs Age: 9 year(s) | Spin-off | Managing Dir.-CEO: Devic (Éric) [founder, born 1966, Pharm.D., Ph.D. molecular biology] Sc.Dir.-CSO: Ginisty (Hervé) [born 1971, Ph.D. molecular biology] Fin.Dir.-CFO: BusDev: Hountondji (Séverine) Financers (Hist.): privately owned, undisclosed | n.a. | 0.45 | Multiple | Subcontractor |
| Helios Biosciences Profile + www.helios-biosciences.com | 2002 | IDF Créteil (near Paris) | Discovery, Targets (also, Contract, Research) Key words: Tissue expression, InSitu Hybridization, Biomarkers, Prostate cancer, Epilepsy, SIMPathway Mission: to research for own pipeline or to provide third parties with proprietary tools in the identification and characterization of therapeutic targets and biomarkers Clients: Research labs Age: 7 year(s) | Academic | Managing Dir.-CEO: Dumas (Jean-Baptiste) [founder, born 1958, Ph.D., ex-Genset, Genethon] Sc.Dir.-CSO: Dumas (Sylvie) [Ph.D., Normale Sup, ex-CNRS] Fin.Dir.-CFO: Med.Dir.-CMO: Vujasinovic (Todor) [M.D., ex-CNRS] Financers (Hist.): privately owned (registered capital 2006 = 0.15 M€) | n.a. | n.a. | Cancers | Preclin |
| Hybrigenics Profile + www.hybrigenics.com | 1998 | IDF Paris | Discovery, Drugs (also, Services, Research) Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs), Ubiquitin Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions Clients: Prescribers Age: 12 year(s) | Academic | Managing Dir.-CEO: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)] Clin.Dir.-CMO: Dufourt-Lamartinie (Jean-François) [Ph.D., ex-IGR, BioAlliance] Oper.Dir.-COO: Petitville (Didier) [ex-Institut Pasteur] I.T.Dir.-CIO: Boissy (Guillaume) [Ph.D. molecular biophysics, ex-INSA] Fin.Dir.-CFO: Cohen, Eric [Ms. finance (Dauphine), MBA (LBS), ex-Teva, Mazars, CityJeux, Radio BFM] BusDev: Financers (Hist.): Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public | n.a. | 2.7 | Cancers | Preclin |
| Hyphen BioMed Profile + www.hyphen-biomed.com | 1999 | IDF Neuville-sur-Oise (near Paris) | Design, Diagnostics (also, Discovery, Diagnostics) Key words: Research reagents, Thrombosis, Haemostasis, Auto-Immunity, Zymutest Mission: to develop a full line of innovative kits in diagnostic and research reagents and biochemicals, manual or automated, designed with clotting, chromogenic or immunological methods, for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immunity Clients: Research labs, Pharmaceutical industry Age: 11 year(s) | Personal venture | Managing Dir.-CEO: Amiral (Jean) [born 1952, Ph.D., Immunologist, Biochemist, ex-Serbio Stago (CSO)] Sc.Dir.-CSO: Vissac (Anne Marie) [born 1956, ex-Project Leader Serbio Stago] Fin.Dir.-CFO: BusDev (& sales): Penissard (Véronique) Financers (Hist.): privately owned, IDF Développement, Banque Populaire | n.a. | n.a. | Cardiovasc | Trade |
| Imagene Profile + www.imagene.fr | 1998 | Aquitaine Pessac (near Bordeaux) | Contract, Manufacturing Key words: DNA-conservation, Encapsulation, Extraction Mission: to provide third parties with high quality, long term preservation of DNA at room temperature for large scale genomic resources banks Clients: Research labs Age: 11 year(s) | Personal venture | Managing Dir.-CEO: Tuffet (Sophie) Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): OTC A.M. and Aquitaine Création Investissement | n.a. | 2.0 | Genome | Trade |
| ImmunId Profile + www.immunid.com | 2005 | Rhône-Alpes Grenoble | Contract, Research Key words: Personalized diagnostics, Combinatorial Repertoire analysis, Immunology analysis, Immunodeficiency, Immuno-monitoring, T & B cell repertoire, Genomic DNA, Infectious diseases, Auto-immune diseases, Blood cancers, Lymphoma and Leukemia diagnosis, ImmunTracker, ImmunIg Mission: to provide third parties with innovative diagnostic and prognostic tools and high value-added services to decrease clinical study costs by selecting better immuno-drug candidates and by measuring immuno-reconstitution and suppression kinetics Clients: Research labs, Hospitals, Pharmaceutical industry Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Pasqual (Nicolas) [co-founder, born 1977, Ph.D. molecular biology, ex-CEA] Sc.Dir.-CSO: Pasqual (Nicolas) Oper.Dir.-COO: Weisbuch (Sébastien) [born 1977, Ph.D. nanobiology, ex-CEA] Tech.Dir.-CTO: Mouret (Jean-François) [Pharm.D., ex-Applied Biosystems, Cogenics, Genome Express (co-founder)] Fin.Dir.-CFO: BusDev: Plantier (Nadia) Financers (Hist.): privately owned (registered capital 2006 = 0.053 M€) Note : website revamped in March 2009 | n.a. | n.a. | Multiple | Trade |
| Immutep Profile + www.immutep.com | 2001 | IDF Orsay (near Paris) | Discovery, Immunology (also, Discovery, Diagnostics) Key words: Cancer, Chronic Infectious Diseases, T Cell Immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein Mission: to develop immunostimulatory factors for the treatment of cancer and chronic infectious diseases and immunomodulatory therapeutic antibodies for the treatment of cancers or autoimmune diseases Clients: Prescribers Age: 8 year(s) | Spin-off | Managing Dir.-CEO: Hawken (John B.) [co-founder, born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell] Sc.Dir.-CSO: Triebel (Frédéric) [co-founder, born 1954, M.D., Ph.D. immunology, ex-Inserm, Prof. Immunology, Paris University, Institut Gustave Roussy (IGR)] Fin.Dir.-CFO: BusDev: Financers (Hist.): Innoven Partenaires, H2I | 6.7 | 2.5 | Cancers | Clinical |
| Imstar Profile + www.imstar.fr | 1985 | IDF Paris | Contract, Services Key words: Microscopic imaging, Cell screening, Systems, Instruments, High throughput, Pathfinder Mission: to provide third parties with complete vertical solutions for fully automated high-throughput cellular analysis, in the fields of genotoxicity and environmental toxicity, focused on compound screening, biomonitoring, cytopathology, and dedicated to research, diagnostic, staging and drug discovery Clients: Research labs Age: 24 year(s) | Spin-off | Managing Dir.-CEO: Soussaline (Françoise) [born 1945] Sc.Dir.-CSO: Soussaline (Françoise) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned | n.a. | n.a. | Studies | Subcontractor |
| In-Cell-Art Profile + www.incellart.com | 2005 | Bretagne Nantes | Design, Delivery (also Discovery, Drugs) Key words: Supramolecular nanocarriers, Intracellular delivery, Polypeptide deficiencies, siRNA therapeutics, DNA vaccines, Antibodies production, In vitro transfection Mission: to ascertain the delivery of a drug to the heart of the cell, the prolongation of its bioavailability, the vectorisation of DNA or RNA-based active principles Clients: Pharmaceutical industry, Biotechs, Academic labs Age: 24 year(s) | Personal venture | Managing Dir.-CEO: Peyrot (Alain) [ex-Pharmacia, Sanofi, Mérieux, Wellcome, Wyeth] Sc.Dir.-CSO: Pitard (Bruno) [co-founder, Ph.D., ex-Aventis Pasteur, Rhône Poulenc Rorer, CNRS, Inserm] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.05 M€) | 0.45 | 0.25 | Multiple | Preclin |
| Indicia Biotechnology Profile + www.indicia.fr | 1998 | Rhône-Alpes Lyon | Contract, Research Key words: Microparticle technology, Immunoassay, Reagents, Luminex, OEM dosing methods, OEM production services Mission: to provide third parties with solutions in R&D and manufacturing by providing a complete range of comprehensive services in the areas of immuno-diagnostics, microbiology and sterile reagents Clients: Pharmaceutical industry, Diagnostics industry Age: 11 year(s) | Personal venture | Managing Dir.-CEO: Legastelois (Stéphane) [born 1960, Ph.D. biochemistry, ex-Merck KgAa, Indicia Diagnostics] Oper.Dir.-COO: Panier (Elodie) [Ms.Sc., Eng. IUP, DESS Management] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned Note : initial company registering under Indicia: 1984.03 | n.a. | n.a. | Studies | Subcontractor |
| InGen Biosciences Profile + www.ingen.fr | 2001 | IDF Chilly-Mazarin (near Paris) | Design, Diagnostics Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine, Abag Mission: to design and manufacture protein biomarkers for multiparametric diagnostic in infectious diseases Clients: Pharmaceutical industry Age: 8 year(s) | Start-up | Managing Dir.-CEO: Hermet (Jean-Pierre) [born 1943, ex-Schering-Plough, Wyeth, Bentley, Peptide Immune Ligands (founder), Hybrigenics (founder), Hemosystem (founder)] Sc.Dir.-CSO: Martin (Jacques) [Eng. ESITPA, ex-Clonatec, also Mktg.Dir] Fin.Dir.-CFO: Zelaci (Elisabeth) [IAE] BusDev: Financers (Hist.): Innoven Partners, Société Générale A.M. Note : Ingen website, acquired in 2006, updated with Ingen Biosciences (no company website ever as Abag) | 8.0 | 6.0 | Infections | Trade |
| Innate Pharma Profile + www.innate-pharma.com | 1999 | Méditerranée Marseille | Discovery, Drugs Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer, IPH 4201 Mission: to develop first in class drugs targeting the innate immune system Clients: Prescribers Age: 10 year(s) | Start-up | Managing Dir.-CEO: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter] Sc.Dir.-CSO: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter] Clin.Dir.-CMO: Rozencweig (Marcel) [M.D., ex-BMS] Fin.Dir.-CFO: Boissel (Stéphane) [ex-Lazard] BusDev: Shah (Hemansu) [Ph.D., MBA, ex-GPC Biotech, BMS, J&J] Financers (Hist.): Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public | 125.3 | 23.1 | Cancers | Clinical |
| InnaVirVax Profile + www.innavirvax.fr | 2008 | IDF Évry (near Paris) | Discovery, Immunology (also, Discovery, Diagnostics) Key words: HIV, CD4 restoration, Predictive test Mission: to develop a new HIV therapeutic vaccine aiming to restore CD4 to normal levels (without immunodeficiency) and to design a diagnostics test able to predict the evolution of the AIDS pathology of a given patient Clients: Pharmaceutical industry Age: 2 year(s) | Start-up | Managing Dir.-CEO: Crouzet (Joël) [born 1958, Ph.D., Eng. Agro (Grignon), ex-Eurobiobiz, Inserm Transfert, Neurotech, APCells, Rhône-Poulenc Rorer] Sc.Dir.-CSO: Crouzet (Joël) Fin.Dir.-CFO: Proj.Mgr.: Ho Tsong Fang (Raphaël) [Vet.D., Ph.D. microbiology and medical virology, ex-Institut Pasteur, UCLA (Los Angeles)] Financers (Hist.): undisclosed | 2.7 | 1.1 | HIV | Incub |
| Innovative Health Diagnostics Profile + www.ihdiag.com | 2009 | Alsace Strasbourg | Discovery, Diagnostics (also, Contract, Research) Key words: Alzheimer, Biomarkers, DiagAlz Mission: to develop and sell diagnostic solutions in the field of neurodegenerative diseases, based on detection of specific biological blood markers Clients: Prescribers, Hospitals Age: 1 year(s) | Personal venture | Managing Dir.-CEO: Regnaut (Xavier) [co-founder, born 1964, Eng. Agro, Ms. Genetics, EMBA HEC] Sc.Dir.-CSO: de Barry (Jean) [co-founder, Ph.D., Eng. Chemistry, ex-Inserm) Clin.Dir.-CMO: Sellal (François) [co-founder, M.D., Pharm.D., ex-CM2R] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2009 = 0.05 M€) Note : IHD is the trade mark company name | n.a. | n.a. | Preclin | Proof-of-Concept |
| IntegraGen Profile + www.integragen.com | 2000 | IDF Évry (near Paris) | Discovery, Diagnostics Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP Mission: to research in gene targets and to market molecular diagnostics products and services that provide clinicians with new tools of personalized diagnosis, treatment, and therapy Clients: Prescribers Age: 9 year(s) | Spin-off | Managing Dir.-CEO: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba] Sc.Dir.-CSO: Hager (Jörg) [co-founder, Ph.D., ex-Pasteur Lille] I.T.Dir.-CIO: Gesnouin (Philippe) [co-founder, ex-Xeotron, Lexicon Genetics] Fin.Dir.-CFO: Court (Patrick) [born 1958, Sup de Co (Paris), ISG] SalesMktg: Martin (Emmanuel) [Pharm.D., ex-Applied Biosystems] BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza] Financers (Hist.): CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM | 16.3 | 2.0 | Cardiovasc | Clinical |
| Ipsogen Profile + www.ipsogen.com | 1999 | Méditerranée Marseille | Discovery, Diagnostics Key words: Assays, Molecular expression, Biomarker, Blood cancer, Leukemia Mission: to develop and market molecular diagnostic tests designed to map diseases in order to guide patient and oncologists decision along their complex therapeutic path (trade mark logo : Ipsogen, cancer profiler) Clients: Research labs, Prescribers Age: 10 year(s) | Personal venture | Managing Dir.-CEO: Fert (Vincent) [co-founder, born 1959, Ms. immunology, ex-Immunotech, Beckman Coulter] Sc.Dir.-CSO: Hermitte (Fabienne) [co-founder, Ph.D., INA, ex-Rhône Poulenc, CNRS] Oper.Dir.-COO: Debono (Stéphane) [born 1975, ESIM, ex-Immunotech, Beckman Coulter] Med.Dir.-CMO: Peyro-Saint-Paul (Hélène) [M.D. (Neurology), MBA (Essec), ex-B.M.S., Actelion, Serono] Fin.Dir.-CFO: Boissel (Pascale) [HEC, ex-Price Waterhouse Coopers, Danone, Lafarge] SalesMktg: Danan (Corinne) [ISC, MBA (Insead, 1990), ex-Monogram Biosciences, Eli Lilly] BusDev: Financers (Hist.): Samenar (Caisse d'Epargne), Institut Paoli-Calmettes, Société Générale A.M., Matignon Technologies, Innovéris, Connecticut Innovations, Viveris, Natixis, Octalia, Public | 24.3 | 2.5 | Cancers | Trade |
| I-Stem Profile + www.istem.eu | 2004 | IDF Évry (near Paris) | Discovery, Drugs (also, Contract, Research) Key words: Stem cells, Monogenic diseases, Drug Discovery, Cell therapy, Pathological modelling, HTS & HCS Mission: to develop new treatments based on the potential offered by pluripotent stem cells (human embryonic cells and iPS) and applicable to rare diseases of genetic origin Clients: undisclosed Age: 5 year(s) | Start-up | Managing Dir.-CEO: Peschanski (Marc) Sc.Dir.-CSO: Peschanski (Marc) Fin.Dir.-CFO: Zakhia (Raymond) BusDev: Duprat (Sébastien) [born 1975, D.E.A. Biology, ex-ESTOOLS, Scientific Research Helsinki-Lille] Financers (Hist.): INSERM, AFM (French Muscular Dystrophy Association) Note : a public-private Institute equally funded by INSERM and AFM, on a yearly budget (about 7 M€ each year between 2005 and 2008) | n.a. | 7.5 | Multiple | Incub |
| Karcinolys Profile + www.no-website.net | 2005 | Rhône-Alpes Lyon | Development, Drugs Key words: Biologicals, Liver cancer, Herpes virus Mission: to develop a new generation of tumour-selective «replication conditional» HSV-1 derived oncolytic viruses Clients: Pharmaceutical industry Age: 4 year(s) | Start-up | Managing Dir.-CEO: Béjot (Jean-Luc) [born 1957, M.D., ex-OPI, Novartis, Quintiles, Genzyme, Ipsen, Cassenne] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.09 M€) | n.a. | n.a. | Cancers | Incub |
| Keosys Profile + www.keosys.com | 2001 | Bretagne Saint Herblay (near Nantes) | Development, Devices Key words: Nuclear medicine, Digital imaging, Radiology, Mammography, I.T. programmes, Visio+, Positoscope Mission: to develop new imaging and communication systems for nuclear medicine and radiology Clients: Distributors or directly to Hospitals, Clinics, Cancer centers, Radiologists Age: 9 year(s) | Start-up | Managing Dir.-CEO: Fortineau (Jérôme) [born 1968, co-founder, Eng., ex-Alcatel] Sc.Dir.-CSO: Terve (Pierre) Fin.Dir.-CFO: BusDev: Financers (Hist.): Lumiplan, Vizille Capital Innovation (CIC group), Pays de Loire Développement, Sodera | n.a. | 1.5 | Cancers | Trade |
| LibraGen Profile + www.libragen.com | 2001 | Midi-Pyrénées Toulouse | Design, Manufacturing (also, Contract, Research) Key words: Bioprocesses, Enzymes, Bio-catalysis, Meta-Dna libraries, Small molecules identification, Micro-organisms, Auriose Mission: to discover, develop and improve innovative bioprocesses for the industrial production of healthcare molecules, by building on bacterial diversity, based on cooperation with 4 Public research units (Inra, Insa, Lyon CNRS, Orsay CNRS) Clients: Pharmaceutical industry, Chemical industry, Cosmetics industry, Food industry Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Nalin (Renaud) [born 1967, Ph.D., ex-CRO] Sc.Dir.-CSO: Lefèvre (Fabrice) [Ph.D., Insa, ex-Protéus] Fin.Dir.-CFO: BusDev: Financers (Hist.): Bioam, Galia Gestion | 3.0 | 2.2 | Studies | Proof-of-Concept |
| Magnisense Profile + www.magnisense.com | 2003 | IDF Rosny-sous-Bois (near Paris) | Discovery, Diagnostics Key words: Magnetic immunoassays, In-vitro diagnostics, Point-of-Care, Rapid tests, Super-paramagnetic particles, Magnetic detection, Portable reader, Cardiac markers, Infections, MIAtek Mission: to develop and market next-generation magnetic immunoassays that improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing (immunoassays that are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods) Clients: Diagnostic industry Age: 6 year(s) | Start-up | Managing Dir.-CEO: Lenglet (Luc) [born 1964, Ph.D., Normale Sup (Paris), ex-Rhodia, Arthur D. Little] Sc.Dir.-CSO: Nikitin (Petr) [Ph.D.] Fin.Dir.-CFO: RegMktg: El Yousfi (Hayat) [Mme, Pharm.D.] BusDev: Péquignot (Clayton) [Ms. Biotechnology, ex-Cap Gemini Ernst and Young, Venstrata] Financers (Hist.): Baring Vostok Capital Partners, Psilos Group, Seventure, Creadev (registered capital 2007 = 0.1 M€) Note : legal foundation, February 20. 2007 (not 2003, as per company) | 6.0 | n.a. | Point of Care Testing | Trade |
| Mapreg Profile + www.mapreg.com | 2000 | IDF Le Kremlin-Bicêtre (near Paris) | Discovery, Drugs Key words: Microtubules, CNS diseases, Spinal cord injury, Traumatic brain injury, Neurosteroids Mission: to dscover new drugs based on a novel mechanism for the protection and repair of nerve connections Clients: Pharmaceutical industry (own development up to phase II included) Age: 9 year(s) | Academic | Managing Dir.-CEO: Baulieu (Etienne Emile) [born 1926, M.D., Ph.D.] Sc.Dir.-CSO: Robel (Paul) [M.D.] Oper.Dir.-COO: Le Bouteiller (Denis) [Eng. Centrale (Lyon), Ms. sciences, MBA] Fin.Dir.-CFO: BusDev: Financers (Hist.): | 2.0 | n.a. | CNS | Preclin |
| MAT Biopharma Profile + www.matbiopharma.fr | 2000 | IDF Évry (near Paris) | Discovery, Drugs Key words: MABs, Antibody-based therapeutics, Cancer, Immuno-therapy, Angiogenesis Mission: to develop proprietary antibody-based therapeutics for the treatment of cancer Clients: Pharmaceutical industry (own development up to phase II included) Age: 10 year(s) | Personal venture | Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)] Sc.Dir.-CSO: Boumsell (Laurence) Fin.Dir.-CFO: vacant BusDev: vacant Financers (Hist.): Génopole 1er Jour, IxCore, Anvar Note : full company legal name is Monoclonal Antibodies Therapeutics | 5.8 | 5.8 | Cancers | Clinical |
| Mauna Kea Technologies Profile + www.maunakeatech.com | 2000 | IDF Paris | Discovery, Diagnostics Key words: Fluorescence, Fiber optic, Microscopy, Pneumology, Gastrology, CellVizio Mission: to develop in vivo cellular imaging systems for biomedical and medical applications Clients: Specialist doctors Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Loiseau (Sacha Alexandre) [co-founder, born 1970, Ph.D., Eng. École Polytechnique, ex-CNES] Sc.Dir.-CSO: Lacombe (François) [Ph.D. astrophysics, Normale Sup] Oper.Dir.-COO: Carl (Tharcisse) [Eng. Ecole Centrale (Lyon), ex-Teleflex Medical] Fin.Dir.-CFO: Garnier (Caroline) [Sup de Co (Reims), DECS, ex-Guerbet] BusDev: Financers (Hist.): Psilos Group, Seventure, CreAdev | n.a. | 20.5 | Multiple | Trade |
| Medesis Pharma Profile + www.medesispharma.com | 2003 | Midi-Pyrénées Baillargues (near Montpellier) | Discovery, Drugs Key words: Nanotechnology drug delivery systems, Metals low doses, Vanadium, Manganese, Strontium, Metabolic syndrome, Diabetes Mission: to develop new innovative treatments of diabetes and neurodegenerative disorders based on metallic ions technology Clients: undisclosed Age: 6 year(s) | Personal venture | Managing Dir.-CEO: Maurel (Jean-Claude) [founder, born 1946, M.D., M.Sc., ex-Natura Medica (founder)] Sc.Dir.-CSO: Oper.Dir.-COO: Cudenec (Claude-Alain) [Ph.D., ex-Servier, Pierre Fabre] Fin.Dir.-CFO: BusDev: Jackson (Peter) Financers (Hist.): privately owned | n.a. | n.a. | Multiple | Preclin |
| Mellitech Profile + www.mellitech.com | 2005 | Rhône-Alpes Grenoble | Discovery, Drugs (also, Design, Diagnostics) Key words: Type 2 diabetes, Zinc transporter protein Mission: to develop a new therapeutic and diagnostic approach to type II diabetes based on a proprietary (PCT) zinc transporter protein, only present in insulin-secreting cells Clients: undisclosed Age: 4 year(s) | Spin-off | Managing Dir.-CEO: Platford (Richard) [Ms. mechanical sciences (Cambridge), MBA (LBS), ex-PricewaterhouseCoopers, Cellvir] Sc.Dir.-CSO: Chimienti (Fabrice) [Ph.D.] Oper.Dir.-COO: Girod-Roux (Pierre-Marie) [also board chairman, DEA (Physiology), Ms. management] Fin.Dir.-CFO: BusDev: de Boysson (Yann) [co-founder] Financers (Hist.): privately owned (registered capital 2006 = 0.08 M€) | 0.5 | 0.5 | Cardiovasc | Preclin |
| Metabolys Profile + www.metabolys.org | 2008 | Rhône-Alpes Lyon | Contract, Research Key words: Metabolomics, Toxicity, Drug candidate Mission: to improve the preclinical evaluation of drug candidates through cellular metabolomics in pharmacology, toxicology and nutrition (identification and quantification of metabolic pathways by the combination of enzymatic and carbon 13 NMR measurements with mathematical models of metabolic pathways) Clients: Pharmaceutical industry, Research labs Age: 1 year(s) | Spin-off | Managing Dir.-CEO: Baverel (Gabriel) [born 1947, founder, M.D., University Prof. Lyon] Sc.Dir.-CSO: Baverel (Gabriel) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2008 = 0.15 M€) | 0.15 | 0.15 | Testing | Proof-of-Concept |
| MicroBioChips Profile + www.microbiochips.com | 2006 | IDF Paris | Design, Diagnostics Key words: Biochip, Micro-arrays, Cytokine, Anti-body, MicroVigene Mission: to speed up third parties research with customized designed micro-arrays and to exclusively distribute in Europe micro-arrays from other biotech companies (also to develop own micro-arrays, as nano-arrays, in partnership with Toulouse CNRS) Clients: Pharmaceutical industry, Agro industry, Cosmetics industry Age: 3 year(s) | Personal venture | Managing Dir.-CEO: Saulot (Vincent) [co-founder, born 1975, Ph.D., Eng. Insa, ex-BioMedical Diagnostic, Chiron] Sc.Dir.-CSO: Malingue (Frédéric) [ex-Biorad] Fin.Dir.-CFO: BusDev: Azadian (Pascal) [co-founder, ex-other biotechs] Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) | 0.3 | 0.3 | Multiple | Trade |
| MilleGen Profile + www.millegen.com | 1999 | Midi-Pyrénées Labège (near Toulouse) | Contract, Manufacturing (also, Development, Drugs) Key words: Directed Molecular Evolution (DME), MutaGen, Mutascreen, Gene cloning, High throughput screening, Antibodies, Peptides Mission: to develop and and genetically engineer new human therapeutic antibodies based on proprietary Directed Molecular Evolution platform, for third parties and for own pipeline (also, to offer custom services including high-throughput DNA sequencing, bioinformatics, gene cloning and vector development services, peptides synthesis and antibodies engineering and production) Clients: Pharmaceutical industry, Research labs, Biotechs Age: 10 year(s) | Personal venture | Managing Dir.-CEO: Kharrat (Abdel Hakim) [co-founder, born 1961, Ph.D. biology, Ms. Management, ex-EMBL Heidelberg] Sc.Dir.-CSO: Bouayadi (Khalil) [co-founder, Ph.D. molecular pharmacology] I.T.Dir.-CIO: Crozet (Fabien) [Ph.D. molecular neurobiology] Fin.Dir.-CFO: BusDev: Deflisque (Anne) [Ms. biochemistry, ex-GE Healthcare] Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€) | 0.6 | 0.6 | Multiple | Subcontractor |
| MitoProd Profile + www.mitoprod.com | 2004 | Aquitaine Bordeaux | Contract, Manufacturing Key words: RNA-factory, Mitochondrial DNA, Yeast, Custom nucleotides, RNA Genix Mission: to use proprietary technology of RNA production based on its own exclusive license in order to produce most promising molecules for third parties Clients: Pharmaceutical industry Age: 5 year(s) | Personal venture | Managing Dir.-CEO: Plane (Guillaume) [born 1978, co-founder, Ms. biochemistry (Bordeaux)] Sc.Dir.-CSO: Fin.Dir.-CFO: Perrin (Patrick) [Ms. economy, ex-Flamel Technology, Ernst&Young] Techn.Dir.-CTO: Schaal (Oriane) [Ph.D., ex-Covalab] BusDev: Amandine (Jacques) Financers (Hist.): Aquitaine Création Innovation, Business angels, privately owned | 2.2 | 1.6 | Multiple | Trade |
| Murigenetics Profile + www.murigenetics.com | 2005 | Méditerranée Marseille | Discovery, Drugs Key words: Genetic diseases, Charcot-Marie-Tooth (CMT), Hereditary neuropathy, Genetic mental disorders Mission: to develop new drugs for the treatment of serious genetic diseases, based on internal production of genetically modified animal models expressing human genes of patients with hereditary peripheral neuropathies, or mental retardation Clients: Prescribers Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Le Boulay (Morgane) [born 1981, Eng. Centrale, ex-BCG] Sc.Dir.-CSO: Oper.Dir.-COO: Berro (Marine) Fin.Dir.-CFO: BusDev: Financers (Hist.): grants by Association Française pour le traitement de la Myopathie (AFM, i.e. French Muscular Dystrophy Association), privately owned (registered capital 2006 = 0.04 M€) | n.a. | n.a. | Genome | Preclin |
| Mutabilis Profile + www.mutabilis.fr | 2001 | IDF Romainville (near Paris) | Discovery, Drugs Key words: Antibacterials, Severe infections, Nosocomial diseases Mission: to identify and develop new antibacterial therapies in the fields of vaccines, antibodies and classic antibiotics Clients: Prescribers Age: 8 year(s) | Spin-off | Managing Dir.-CEO: Stéphane Huguet [born 1955, President P.O.I., ex-Pharmacia, Phoenix, Fournier, Sandoz] Sc.Dir.-CSO: Escaich (Sonia) [Ph.D., ex-Sandoz, Rhône Poulenc] Fin.Dir.-CFO: BusDev: Financers (Hist.): Bioam, AXA P.E., Inserm-Transfert, Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.) Note : website revamped in May 2008, URL changed from «.com» to «.fr» in December 2009 with a single page and mention of company owned by Pharma Omnium International | 10.2 | 8.0 | Infections | Clinical |
| Myosix Profile + www.myosix.com | 2000 | IDF Paris | Discovery, Immunology Key words: Cell Transplantation, Muscle cells, Myopathies, Saint-Louis, Genzyme Mission: to develop cell-based therapies for diseases with unmet medical needs, such as myopathies, based on expertise in muscle cell technology Clients: Hospitals Age: 9 year(s) | Academic | Managing Dir.-CEO: Turner (Frederic) [Genzyme] Sc.Dir.-CSO: Dalle (Bruno) [Pharm.D.] Fin.Dir.-CFO: BusDev: Ritsou (Elena) Financers (Hist.): privately owned (51%), Genzyme (49%) | n.a. | n.a. | Muscle | Clinical |
| NanoBiotix Profile + www.nanobiotix.com | 2003 | IDF Paris | Design, Drugs Key words: Nanoparticles, Cancer, NanoXray Mission: to develop new cancer treatments based on proprietary NanoXray platform, as an injection of patented X-ray activated nanoparticles Clients: Hospitals Age: 7 year(s) | Personal venture | Managing Dir.-CEO: Levy (Laurent) [co-founder, born 1971, Ph.D. physical chemistry, ex-Altran] Sc.Dir.-CSO: Oper.Dir.-COO: Boussaha (Kader) [co-founder, born 1973, Eng. ENI, ex-Altran] Med.Dir.: Borghi (Elsa) [M.D., ex-Sanofi-Aventis] Fin.Dir.-CFO: BusDev: Financers (Hist.): Cap Décisif, Amorçage Rhône Alpes, Matignon Technologies, OTC Asset Management | 8.0 | 7.0 | Preclin | Preclin |
| Neorphys Profile + www.neorphys.com | 2005 | Méditerranée Nîmes | Discovery, Drugs Key words: Female desire dysfunction, Nausea-free acute pain, Morphine derivatives, Analgesics Mission: to develop a new family of opioid analgesic drug candidates with low side effects, especially on the gastrointestinal transit, with a specific focus on visceral pain relief Clients: Pharmaceutical industry (own development to phase IIb) Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Lahana (Roger) [co-founder, born 1954, ex-Syntem] Sc.Dir.-CSO: Oper.Dir.-COO: Larbouret (Karine) [co-founder, ex-Syntem] Fin.Dir.-CFO: BusDev: Financers (Hist.): Soridec, Inserm-Transfert, CEA Valorisation, Fa Diese 2, Seillans, plus independent business angels | 2.3 | 1.2 | Multiple | Preclin |
| Neovacs Profile + www.neovacs.com | 1993 | IDF Paris | Discovery, Immunology Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids Mission: to develop anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases Clients: Prescribers Age: 16 year(s) | Spin-off | Managing Dir.-CEO: Fanneau de la Horie (Guy-Charles) [born 1959, Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough] Sc.Dir.-CSO: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur] Fin.Dir.-CFO: BusDev: Whitehead (Piers) [Oxford, ex-VaxGen, Mercer Management Consulting] Financers (Hist.): Truffle Ventures, Europe Innovation, Debiopharm, Novartis | n.a. | 13.0 | Cancers | Clinical |
| Netris-Pharma Profile + www.no-website.net | 2008 | Rhône-Alpes Lyon | Discovery, Drugs Key words: Breast cancer, Metastasis, Dependence receptors, Targeted Therapy Mission: to develop therapeutic compounds for the treatment of cancer, in particular of breast cancer and NSC Lung cancer Clients: undisclosed Age: 1 year(s) | Personal venture | Managing Dir.-CEO: Pasquier-Desvignes (Rodolphe) [co-founder, born 1968, Edhec 1989, ex-Merck KGaA, PWC] Sc.Dir.-CSO: Bernet (Agnès) [co-founder, CNRS] Fin.Dir.-CFO: BusDev: Financers (Hist.): | n.a. | n.a. | Cancers | Proof-of-Concept |
| Neuronax Profile + www.neuronax.com | 2003 | Centre Saint Beauzire (near Clermont-Ferrand) | Discovery, Drugs (also Contract, Services) Key words: Neural repair, Parkinson disease, Ataxy, NX peptides Mission: to develop new drugs for neural repair in cases of neuro-traumas and neuro-degenerative disorders Clients: Pharmaceutical industry (out-licensing after proof-of-concept) Age: 6 year(s) | Spin-off | Managing Dir.-CEO: Gobron (Stéphane) [born 1968] Sc.Dir.-CSO: Gobron (Stéphane) Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) | n.a. | n.a. | CNS | Proof-of-Concept |
| NicOx Profile + www.nicox.com | 1996 | Méditerranée Nice | Delivery, Drugs Key words: Nitric oxide, Inflammation, Cardio-metabolic, Osteo-arthritis Mission: to develop and market investigational nitric oxide-donating drugs to meet unmet medical needs, based on proprietary nitric oxide-donating technology Clients: Prescribers Age: 14 year(s) | Start-up | Managing Dir.-CEO: Garufi (Michele) [co-founder, born 1954, Pharm.D., ex-Recordati, Italfarmaco] Sc.Dir.-CSO: Pfister (Pascal) [M.D., Pharm.D., ex-Novartis, Sandoz] Fin.Dir.-CFO: Castaldi (Eric) BusDev: Spencer (Gavin) SalesMktg: Sharma (Sanjiv) Financers (Hist.): Apax Partners, Sofinnova, European Medical Ventures, Paribas P.I., Health Capital AB, Oppenheimer Funds, QVT Fund, AQR Capital Management, Pfizer Overseas, Baker Brothers Investments, Public, Managers (less than 3% in 2008) | 380 (over) | 100 | Multiple | Pre-reg |
| Nokad Profile + www.nokad-technology.com | 2004 | IDF Évry (near Paris) | Discovery, Targets Key words: Secreted proteins inactivation, Functional knock-out, Protein vaccination, Mammals Mission: to develop and market functional inactivation (knock-out) of secreted endogenous proteins in mammals, through direct in vivo induction of a specific immune response against an endogenous target Clients: Pharmaceutical industry, Research labs Age: 6 year(s) | Personal venture | Managing Dir.-CEO: Abina (Amine, Mohammed) [co-founder, born 1963, M.D. immunology, Ph.D., ex-AFSSAPS] Sc.Dir.-CSO: Erard (François) [Ph.D., University Professor, ex-Novartis] Fin.Dir.-CFO: Yachou (Abdelkader) [Ph.D. molecular biology, MBA] BusDev: Financers (Hist.): Cap Décisif and Genopole 1er Jour, SHAM (Société Hospitalière d’Assurances Mutuelles), privately owned | n.a. | 1.6 | Studies | Trade |
| Nosopharm Profile + www.nosopharm.com | 2009 | Méditerranée Nîmes | Discovery, Drugs Key words: Anti-infectives, Clostridium difficile, Multi-resistant Gram-negative pathogens Mission: to discover and develop novel antibiotics against nosocomial and emerging infections Clients: Biotechs, Pharmaceutical industry (own development up to phase I) Age: 1 year(s) | Personal venture | Managing Dir.-CEO: Villain-Guillot (Philippe) [co-founder, born 1977] Sc.Dir.-CSO: Gualtieri (Maxime) [co-founder, ex-CNRS] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2009 = 0.02 M€) | n.a. | n.a. | Infections | Proof-of-Concept |
| Nova Decision Profile + www.novadecision.com | 2007 | Méditerranée Montpellier | Contract, Research Key words: Computational chemistry, Predictive-interpretative model building, QSAR/QSPR datamining, Structure-Activity relationships, SARA platform Mission: to provide third parties with medicinal chemistry oriented tools and services (chemo-informatics, molecular modelling and bio-informatics) from Hit Identification to Lead Optimisation Clients: Pharma industry, Agro industry, and Biotechs Age: 2 year(s) | Personal venture | Managing Dir.-CEO: Yasri (Aziz) [founder, Ph.D., born 1966] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned | n.a. | n.a. | Studies | Subcontractor |
| Novagali Profile + www.novagali.com | 2000 | IDF Évry (near Paris) | Delivery, Drugs Key words: Ophthalmology, Conjunctivitis, Dry eye, Glaucoma, Retinopathies, Novasorb, Eyeject, Cationorm Mission: to develop a broad portfolio of innovative ophthalmic products addressing the numerous needs of patients suffering from ocular conditions Clients: Pharmaceutical industry (own development up to registration) Age: 9 year(s) | Start-up | Managing Dir.-CEO: Martinez (Jérôme) [born 1960, Pharm.D., Pharmaco-economics, HEC, MBA, ex-Ethypharm, Lavipharm, Roussel Uclaf, Alliance Santé] Sc.Dir.-CSO: Lambert (Grégory) [Ph.D.] Fin.Dir.-CFO: Garcia (Philippe) [born 1964, Ms. Finance, CPA, ex-Floreane, Goodrich, EuroCave, Deloitte & Touche] BusDev: Garrigue (Jean-Sébastien) [Pharm.D., MBA, ex-Batelle] Financers (Hist.): CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E., Edmond de Rothschild I.P., Siparex, Bernard Chauvin (B.A.) | 59.0 | 15.0 | Ophthalmo | Launch |
| NovoCIB Profile + www.novocib.com | 2005 | Rhône-Alpes Lyon | Contract, Research (also, Discovery, Drugs) Key words: Nucleotides, Antivirals, HCV, Enzymes, Precice platform Mission: to provide third parties with a wide range of products and services, as nucleoside kinase phosphorylation assays, IMPDH or PNP inhibition assays, nucleotides and nucleosides bio-analysis, in cell extract or body fluids (including clinical samples) or the evaluation of the metabolic impact of compounds intended for therapeutic applications in oncology and virology or as immunosuppressive agents, and to develop own anti-viral nucleoside analogues Clients: Pharmaceutical Industry, Biotechs Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Godard (Nicolas) [Ms. microbiology (INA), MBA] Sc.Dir.-CSO: Balakireva (Larissa) [founder, born 1966, Ph.D. Cell Biology, ex-IBS] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) | n.a. | n.a. | Virus | Subcontractor |
| Novotec Profile + www.novotec-labs.com | 1997 | Rhône-Alpes Lyon | Contract, Manufacturing Key words: Antibodies, Extra cellular matrix (ECM) Mission: to develop, produce and distribute species specific antibodies directed against macro-molecules of the Extracellular Matrix (ECM) Clients: Pharmaceutical industry, Biotechs, Research labs Age: 12 year(s) | Spin-off | Managing Dir.-CEO: Guerret (Sylviane) [born 1950] Sc.Dir.-CSO: Hartmann (Daniel) Fin.Dir.-CFO: BusDev: Prulières (Franck) Financers (Hist.): privately owned (registered capital 2006 = 0.065 M€) Communication: no website news update since 2006 in October 2008 | n.a. | n.a. | Multiple | Subcontractor |
| Obe Therapy Profile + www.obetherapy.com | 2000 | IDF Évry (near Paris) | Discovery, Targets (also, Discovery,, Drugs) Key words: Gene targets, Intestine, Obesity, Hyper-cholesterolemia, Type II diabetes Mission: to discover new targets and to develop new drugs for obesity, hypercholesterolemia and type II diabetes, based on the identification of gene targets associated with a lean phenotype Clients: Pharmaceutical industry Age: 10 year(s) | Personal venture | Managing Dir.-CEO: Sc.Dir.-CSO: Harosh (Itzik Isaac) [founder, born 1954, Ph.D., ex-GlaxoWelcome, CNRS, Technion (Israel)] and Braud (Sandrine) [also COO, Ph.D., ex-CEA, Institut Pasteur] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€) | 0.7 | 0.3 | Cardiovasc | Preclin |
| Oligovax Profile + www.oligovax.com | 2000 | IDF Paris | Discovery, Immunology Key words: Oligo-nucleotides, Immuno-stimulants, Cancer, Liténimod Mission: to develop innovative anti-cancer therapies belonging to a new therapeutic class, TLR9 agonists Clients: Prescribers Age: 9 year(s) | Start-up | Managing Dir.-CEO: van der Schueren (Paul) [founder, born 1963, MBA] Sc.Dir.-CSO: Richard (Margaretha) [Pharm.D., ex-Pierre Fabre, AP-HP] Fin.Dir.-CFO: BusDev: Financers (Hist.): Global Millenium Fund Communication: no website news update since 2006, no legal information available since end 2005 Note : webhosting with Lycos withdrawn in March 2009 | n.a. | n.a. | Cancers | Clinical |
| Oncodesign Profile + www.oncodesign.fr | 1995 | Rhône-Alpes Dijon | Contract, Research (also, Discovery, Therapies) Key words: In-vivo screening, Nude-rat, Cancer, Drug resistance, Translational research, Neurology Mission: to provide third parties with preclinical evaluation of novel anticancer therapeutics and to identify and validate molecular targets involved in cancer pathologies Clients: Pharmaceutical industry Age: 15 year(s) | Personal venture | Managing Dir.-CEO: Genne (Philippe) [co-founder, born 1961, Ph.D.] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Ewing (Jonathan) Financers (Hist.): CDC, Avenir Entreprise Gestion, Banque de Vizille | n.a. | 3.0 | Studies | Subcontractor |
| Oroxcell Profile + www.oroxcell.com | 2004 | IDF Romainville (near Paris) | Contract, Services (also, Delivery, Drug) Key words: Skin models (human), Pre-clinical testing, Drug delivery pre-formulation, Innovative formulations, Oral bioavailability Mission: to conduct preclinical studies (in vitro ADME, Animal PK on rodents, Phys-Chem testing, Bioanalysis) for third parties, plus to develop own research in cell culture and innovative formulations, financed by CRO cash-flow Clients: Pharmaceutical industry, Research labs, Cosmetic industry, Food industry, Veterinary industry Age: 5 year(s) | Personal venture | Managing Dir.-CEO: Pachot (Jean) [founder, born 1960, Eng. biochemistry, ex-Roussel Uclaf, Aventis] Sc.Dir.-CSO: Pachot (Jean) Chem.Dir.-CTO: Dini (Christophe) [born 1962, ex-Roussel Uclaf, Aventis] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2007 = 0.3 M€) | n.a. | n.a. | Studies | Subcontractor |
| Oxincell Profile + www.oxincell.com | 2006 | Méditerranée Montpellier | Contract, Services Key words: Mitochondria, Oxymetry measurement, Toxicology, Antivirals Mission: to provide third parties with optimized oximetric analysis of mitochondrial activity Clients: Pharmaceutical industry, Biotechs, Research labs Age: 3 year(s) | Personal venture | Managing Dir.-CEO: Peyreigne (Christelle) [co-founder, born 1969, Ph.D. physiology, Inserm] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned Communication: no website news update since 2006 in February 2010 | n.a. | n.a. | Virus | Preclin |
| Palumed Profile + www.palumed.com | 2000 | Midi-Pyrénées Toulouse | Discovery, Drugs Key words: Anti-malarial, Antibacterial, Covalent bi-therapy, Trioxaquines Mission: to develop new antimalarial agents and also new antibacterial molecules and chelating agents for the treatment of neurodegenerative diseases Clients: Pharmaceutical industry (Sanofi-Aventis) Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Meunier (Bernard) [born 1947, ex-Polytechnique (Professor), CNRS (President)] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Meunier-Chesny (Claudine) [born 1949] Financers (Hist.): IRDI, SOCRI, FCJE (CDC), GSO Capital, Viveris | n.a. | n.a. | Infections | Preclin |
| PharmaLeads Profile + www.pharmaleads.com | 2000 | IDF Paris | Design, Drugs (also, Discovery, Drugs) Key words: Enzymes, Zinc Metallopeptidases, Substrates, Inhibitors, Fluofast, Analgesia Mission: to develop custom design of substrates and inhibitors of all types of proteases for three main applications, on-demand design of optimised substrates and/or inhibitors for pharmaceutical companies, internal drug discovery in the field of analgesia, leading services in botulinum toxin detection and assay Clients: Research labs, Pharmaceutical industry Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Bourbié (Thierry) [born 1952, Polytechnique-Mines, Ph.D. Geophysics, ex-Suez, Schlumberger] Sc.Dir.-CSO: Roques (Bernard Pierre) [Ph.D., ex-Inserm, Polytechnique (Assistant Prof.)] Oper.Dir.-COO: Rogala (Jean-Pierre) [Ph.D. Computer sciences, Eng. Agro, ex-Suez, IBM, Schlumberger] Fin.Dir.-CFO: BusDev: Financers (Hist.): undisclosed | n.a. | n.a. | Multiple | Trade |
| Pharmaxon Profile + www.pharmaxon.com | 2004 | Méditerranée Marseille | Discovery, Drugs (also, Contract, Research) Key words: Cell mobility, CNS Mission: to develop new treatments or new research services to third parties, specialized in controlling cell mobility, as a technological breakthrough in neurology and neuro-oncology Clients: Prescribers, Pharmaceutical industry, Research labs Age: 5 year(s) | Spin-off | Managing Dir.-CEO: Stanley (Glenn) [born 1947, Pharm.D., ex-Rhône-Poulenc Rorer, Marion Merrell Dow, Merck, Amersham Health] Sc.Dir.-CSO: Rougon (Geneviève) [co-founder, Ph.D., ex-CNRS, IBDM] Oper.Dir.-COO: Norreel (Jean-Chrétien) [co-founder, born 1970, Ph.D. neurosciences] Fin.Dir.-CFO: BusDev: Stanley (Glenn) [Pharm.D., ex-Pierre Fabre, Rhône-Poulenc Rorer, Marion Merrell Dow, Merck & Co., Amersham Health] Financers (Hist.): Inserm-Transfert Initiative, Esperante, Primavéris, CAAP Création, SHAM | 2.2 | 1.7 | CNS | Preclin |
| Pharnext Profile + www.pharnext.com | 2007 | IDF Paris | Delivery, Drugs Key words: Drug Repositioning, Charcot Marie Tooth disease, Orphan drugs Mission: to develop innovative treatments for serious neurological diseases, notably peripheral neuropathies (Charcot Marie Tooth, peripheral diabetic neuropathy), and possibly Alzheimer, by implementing a drug repositioning approach which aims to expand the indications for existing medicines Clients: Prescribers Age: 2 year(s) | Start-up | Managing Dir.-CEO: Cohen (Daniel) [co-founder, born 1951, Ph.D., ex-Genset, Millenium] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Truffle Capital Note (February 2010) : the company web site Internet is unavailable and the URL does not exist any more (temporarily ?) | 2.5 | 2.5 | Orphan | Proof-of-Concept |
| PhenoPro Profile + www.phenopro.com | 2007 | Alsace Illkirch (near Strasbourg) | Contract, Services (also, Contract, Research) Key words: Translational medicine, Mouse phenotyping, Targets Mission: to provide third parties with advanced mouse phenotyping-based translational medicine tools and expertise, in order to improve biopharmaceutical drug R&D productivity and patient access to safer and more efficacious drugs Clients: Research labs Age: 2 year(s) | Spin-off | Managing Dir.-CEO: Schaeffer (Catherine) [born 1962] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Allemand (Frédéric) [M.D. cardiology, ex-Hybrigenics, Bayer] Financers (Hist.): privately owned | n.a. | n.a. | Studies | Trade |
| Pherecydes Pharma Profile + www.pherecydes-pharma.com | 2006 | IDF Romainville (near Paris) | Discovery, Drugs Key words: Antibacterials, Phage genes, Emerging problems, Defense, Bio-threat, Libraries of bacteriophages Mission: to develop, then to introduce new products against multi-resistance bacteria, combining surveillance, detection and therapeutic tools based on phage technology, as a bio-defense and bio-security company Clients: undisclosed Age: 3 year(s) | Spin-off | Managing Dir.-CEO: Gabard (Jérôme) [Ph.D., ex-Marketech, DuPont de Nemours] Sc.Dir.-CSO: Iris (François) [co-founder] R&D Dir.-CTO: Pouillot (Flavie) [Ph.D. Microbiology, ex-Institut Pasteur] BusDev: Financers (Hist.): Biosecurity, Financière de Brienne | n.a. | 1.15 | Infections | Preclin |
| PolyIntell Profile + www.polyintell.com | 2004 | IDF-Normandy Val-de-Reuil (south Rouen) | Contract, Research (also, Contract, Manufacture) Key words: Molecularly Imprinted Polymers, MIP, AFFINIMIP, Intelligent polymers, Selectivity, Solid phase extraction, Purification, Miniaturisation, Hydrogel, Sample preparation, Diagnostics Mission: to develop, manufacture and market more accurate analytical and diagnostic tools for pharmaceutical R&D and food safety, plus to operate own research in new polymers, financed by CRO cash-flow Clients: Pharmaceutical industry, Chemical industry, Food industry Age: 5 year(s) | Personal venture | Managing Dir.-CEO: Naraghi (Kaynoush) [co-founder, born 1970, Ph.D., Ms. management] Sc.Dir.-CSO: Bayoudh (Sami) [co-founder, Ph.D.] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned | 0.8 | 0.8 | Studies | Subcontractor |
| PraXcell Profile + www.praxcell.com | 2003 | Midi-Pyrénées Ramonville Saint-Agne (near Toulouse) | Contract, Services Key words: Medical devices, Cellular therapy, Stem cells, Cord blood, Kits, Hematopoietic, Endothelial Mission: to supply human stem cells isolated from cord blood, human Umbilical Vein Endothelial Cells (HUVEC) and human Mesenchymal Stem Cells (MSC) prepared from the umbilical cord for the utilisation of stem cells in the medical, pharmaceutical, cosmetic and biotechnical researches Clients: Research labs Age: 6 year(s) | Personal venture | Managing Dir.-CEO: Eymeri (Michel) [co-founder, born 1954] Sc.Dir.-CSO: Richard (Patrice) [co-founder, M.D.], Zeng (Lin) [co-founder, M.D.] Oper.Dir.-COO: Prévots (Fabien) Fin.Dir.-CFO: BusDev: Financers (Hist.): Galia Gestion, Fonds d’Amorçage Midi-Pyrénées, privately owned Note : all e-mail contacts, rejected (Sept. 2009) | 1.2 | 0.5 | Multiple | Clinical |
| Proteogenix Profile + www.proteogenix-antibody.com | 2003 | Alsace Oberhausbergen (near Strasbourg) | Discovery, Diagnostics (also Contract, Services) Key words: Custom Antibodies, Recombinant proteins, Peptide synthesis, Gene synthesis, Cancer screening, Biomarkers Mission: to discover through targeted screenings new diagnostic markers and to provide third parties with polyclonal and monoclonal antibody development, recombinant protein production and purification, gene synthesis and peptide synthesis Clients: Research labs Age: 7 year(s) | Personal venture | Managing Dir.-CEO: Funfrock (Philippe) [co-founder, born 1978] Sc.Dir.-CSO: Hopfner (Raphaël) Fin.Dir.-CFO: BusDev: Financers (Hist.): Oséo, privately owned Communication: no website news update since 2006 in October 2008 | 0.04 | 0.04 | Cancers | Trade |
| Protéus Profile + www.proteus.fr | 1998 | Méditerranée Nîmes | Design, Drugs Key words: Proteins, Engineering, Manufacturing, Immunoline Mission: to discover, engineer, optimize and manufacture new proteins and protein-based products and processes for third parties and own research Clients: Pharmaceutical industry, Chemical industry (Degussa, Henkel, Aventis/Adisseo, Thales, Veolia Environment) Age: 11 year(s) | Personal venture | Managing Dir.-CEO: Ravot (Gilles) [born 1970, Ph.D. microbiology, Eng. ESIL, ex-Sanofi-Recherche] Sc.Dir.-CSO: Ravot (Gilles) Fin.Dir.-CFO: Vander Linden (Marc) BusDev: Bloch (Jean-François) [also deputy CEO, co-founder, born 1961, Pharm.D., ex-Oris, CEA] Financers (Hist.): PCAS (32%) Notes : fully distinct from US-based biotech company Proteus Biomedical | n.a. | n.a. | Multiple | Trade |
| Protexel Profile + www.no-website.net | 2000 | IDF Paris | Discovery, Drugs Key words: Immunology, Alcoholic hepatitis, Liver cancer, Cirrhosis, Chemical mimetics, Anti-oxydant, Superoxyde dismutase, Mangafodipir Mission: to develop innovative treatments for severe liver conditions Clients: Pharmaceutical industry (own development up to phase III) Age: 9 year(s) | Spin-off | Managing Dir.-CEO: Batteux (Frédéric) [Batteux (Arman), born 1939, legally as President] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): | n.a. | n.a. | Liver | Clinical |
| PX’Therapeutics Profile + www.px-therapeutics.com | 2000 | Rhône-Alpes Grenoble | Contract; Research (also, Contract, Manufacturing) Key words: Recombinant protein engineering Mission: to develop biotherapeutics (valuable recombinant proteins) from early stage research up to cGMP production through its specialized technology and manufacturing platforms Protein’eXpert, PX’Monoclonals and PX’Pharma, for third parties Clients: Pharmaceutical industry, Biotechs Age: 9 year(s) | Personal venture | Managing Dir.-CEO: Rousselle (Tristan) [co-founder, born 1970, Ph.D. cellular biology] Sc.Dir.-CSO: Mouz (Nicolas) [co-founder, born 1966, Ph.D. molecular biology] Prod.Dir.-CTO: Mouz (Sebastien) [Ph.D.] Fin.Dir.-CFO: BusDev: Financers (Hist.): undisclosed, privately owned (registered capital 2007= 0.13 M€) | n.a. | 1.3 | Multiple | Trade |
| Quantum Genomics Profile + www.quantum-genomics.com | 2006 | IDF Massy (near Paris / HQ Jersey City USA) | Discovery, Drugs Key words: Academic, Development platform, Co-partnering R&D Mission: to maximize the developments and discoveries of academic research into breakthrough treatments for human disease, in cardiovascular diseases, neurology and metabolic related diseases Clients: Pharmaceutical industry Age: 4 year(s) | Start-up | Managing Dir.-CEO: Segard (Lionel) [born 1968, Biochemistry, ex-Inserm-Transfert (CEO), IBM, TFSM] Sc.Dir.-CSO: Riffaud (Jean-Pierre) [Pharm.D., ex-Cellpep, NicOx, Fournier, Debat] Fin.Dir.-CFO: BusDev: Financers (Hist.): | 3.0 | 3.0 | Multiple | Preclin |
| Rhenovia Pharma Profile + www.rhenovia.com | 2007 | Alsace Mulhouse | Contract, Research Key words: Alzheimer, Biosimulation, Computational neuroscience, Memory Mission: to contribute to discover new medicines against Alzheimer’s and other central nervous system (CNS) diseases, by developing breakthrough biosimulation platforms for memory and other CNS functions Clients: Pharmaceutical industry, Biotechs Age: 2 year(s) | Personal venture | Managing Dir.-CEO: Bischoff (Serge) [co-founder, born 1948, Ph.D. neuropharmacology, ex-Novartis] Sc.Dir.-CSO: Baudry (Michel) [co-founder, Eng. Ecole Polytechnique, professor engineering (Los Angeles), Ph.D.] Oper.Dir.-COO: Faupel (Michel) [co-founder, ex-Novartis] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned, no outisde investors (registered capital 2007 = 0.126 M€) | 1.0 | 1.0 | CNS | Proof-of-Concept |
| ScarCell Therapeutics Profile + www.scarcell-therapeutics.com | 2007 | IDF Paris | Design, Drugs Key words: Cell therapy project, Transplantation, Cardiovascular Mission: to carry out an autologous gingival fibroblasts transplantation in order to repair injured tissues, in particular in the field of cardiovascular pathology (vascular prosthesis for abdominal aortic aneurysm, atherosclerosis,…) and others Clients: undisclosed Age: 2 year(s) | Spin-off | Managing Dir.-CEO: Augier (Jean-Jacques) [legally as President, born 1953] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): Note : URL not renewed in time (October 2009), still unavailable (February 2010) | n.a. | n.a. | Cardiovasc | Proof-of-Concept |
| Sepal Pharma Profile + www.sepalpharma.com | 2004 | IDF Paris | Discovery, Drugs Key words: Cancer, Jasmonate Mission: to develop jasmonate derivatives as novel anticancer therapies (with its R&D laboratories in Nes Ziona, near Tel-Aviv, Israel) Clients: Prescribers Age: 5 year(s) | Start-up | Managing Dir.-CEO: Revah (Frédéric) [born 1968, Ph.D., Eng. Polytechnique, also Genethon Managing Dir. (2010- ), ex-Cerep, Rhône-Poulenc Rorer] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Herzberg (Max) [born 1940, Ph.D., ex-Orgenics (founder), D-Pharm (founder)] (also, Board Chairman) Financers (Hist.): public (17%), founders (49%) | 3.8 | 3.8 | Cancers | Preclin |
| Serial Genetics Profile + www.serialgenetics.com | 2003 | IDF Évry (near Paris) | Discovery, Diagnostics (also, Contract, Research) Key words: Kits, Biochips, Molecular biology, Mutation discovery, Endo-1 enzyme, HairLoop, SatArray, Charcot Disease Mission: to develop and sell genetics analysis kits based on proprietary technology, HairLoop, and mutation discovery tools, based on the Endo-1 enzyme, to third parties Clients: Research labs, Prescribers Age: 6 year(s) | Start-up | Managing Dir.-CEO: Valat (Christophe) [born 1964, co-founder, Ph.D. biosensors] Sc.Dir.-CSO: Fin.Dir.-CFO: Couget (Noëlle) [Ms. Finance] BusDev: Nicolas (François) [co-founder, Ph.D.] Financers (Hist.): | n.a. | n.a. | Multiple | Trade |
| Sisène Biotechnologies Profile + www.no-website.net | 2007 | IDF Paris | Discovery, Drugs Key words: Cancer, Vegf, Anti-angiogenics Mission: to discover and develop new anti-angiogenic biotherapies Clients: Pharmaceutical industry (own development up to clinical trials) Age: 2 year(s) | Academic | Managing Dir.-CEO: Marsac (Jean) [born 1943, co-founder, M.D., Professor] Sc.Dir.-CSO: Plouët (Jean) [deceased, co-founder, M.D., Ph.D., Professor, Inserm, ex-Abtech, Gencell, AP-HP Lariboisière] Fin.Dir.-CFO: BusDev: Financers (Hist.): ARC, ANR, InCA Note (February 2010) : the company web site Internet is still unavailable and no media report has been submitted since 2008 | 1.3 | 1.3 | Cancers | Preclin |
| Skuld-Tech Profile + www.skuldtech.com | 1999 | Méditerranée Montpellier | Design, Diagnostics (also, contract, research) Key words: Biomarkers, Genomics, Pharmaco-genomics, Bio-informatics, Biosensors, SAGE Mission: to select and validate biomarkers, bioinformatics, biosensors, leading to design new diagnosis, identify new targets, and generate new leads for biopharmaceutical companies and personalized medicine Clients: Research labs Age: 10 year(s) | Spin-off | Managing Dir.-CEO: Ritter (Didier) [co-founder, born 1969, Ms. molecular biology, MBA, ex-Bio2R (founder)] Sc.Dir.-CSO: Piquemal (David) [co-founder, Ph.D., Prof. genomics] Fin.Dir.-CFO: BusDev: Outrebon (Philippe) [co-founder, Ms. sciences, ex-Ernst & Young] Financers (Hist.): Oseo, Regional Territory Body, Private Investors | n.a. | n.a. | Multiple | Preclin |
| Synapcell Profile + www.synapcell.com | 2005 | Rhône-Alpes Grenoble | Contract, Research Key words: Preclinical development, CNS, Epilepsy, Neuronal networks Mission: to provide third parties with customized solutions for preclinical evaluation of CNS therapeutics and with consulting, pre-designed and customized programs to expertise drug candidates of the biopharmaceutical industry, and also to develop own research innovative tools Clients: Research labs Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Roucard (Corinne) [born 1969, co-founder, Ph.D., ex-Synapcell (Project Leader)] Sc.Dir.-CSO: Bressand (Karine) [born 1971, Ph.D.] Fin.Dir.-CFO: Roche (Yann) [born 1974, Ph.D. biology, Ms. Management] BusDev: Roche (Yann) Financers (Hist.): privately owned (registered capital 2006 = 0.09 M€) | n.a. | 0.7 | CNS | Subcontractor |
| Synprosis Profile + www.synprosis.com | 2003 | Méditerranée Marseille | Discovery, Immunology (also Contract, Manufacturing) Key words: HIV1 vaccine, Synthetic peptides Mission: to provide custom peptide synthesis (notably vaccines) in solid phase manufacture with high quality for basic research and for therapeutic applications (cGMP) and to develop own immunological compounds Clients: Pharmaceutical industry Age: 6 year(s) | Personal venture | Managing Dir.-CEO: Salles (Jean-Pierre) [born 1954, Pharm.D., ex-Laphal (Dir. R&D)] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Pomarède (Richard) Financers (Hist.): privately owned (registered capital 2007 = 0.23 M€) | 0.35 | 0.2 | Vaccines | Preclin |
| Tc Land Expression Profile + www.tcland-biotech.com | 2002 | Bretagne Nantes | Design, Diagnostics Key words: Biomarkers, Transplantation, Auto-immune diseases Mission: to develop gene expression biomarkers in transplantation and immunology through proprietary strategy of personalized medicine Clients: Pharmaceutical industry, Research labs Age: 7 year(s) | Spin-off | Managing Dir.-CEO: Huriez (Alain) [born 1962, M.D., MBA, ex-Neovacs, Truffle Capital, GSK, MDS, Innovex/Quintiles, Phoenix] Sc.Dir.-CSO: Guillet (Marina) [born 1973, Ph.D., ex-TcLand (CEO)] Clin.Dir.-CMO: Larcier (Patrick) [Pharm.D., MBA Essec, ex-Neovacs, Biogen-Idec, Quintiles, Parexel, GSK] Fin.Dir.-CFO: Jaffré (Philippe) [MBA, ex-Novartis, Chiron, Dana Capital] BusDev: Clerval (Rodolphe) [Eng. ESIL, ex-Genzyme, Natexis, Aventis] Financers (Hist.): Auriga Partners, Debiopharm, Genzyme Ventures, Quest For Growth, Beviguen | 9.0 | 8.2 | Multiple | Preclin |
| Theraclion Profile + www.theraclion.fr | 2004 | IDF Paris | Development, Devices Key words: Ultrasound, Parathyroidism, Prostate cancer Mission: to develop non-invasive solutions, based on High Intensity Focussed Ultrasound (HiFu), for the treatment of secondary hyperparathyroidism and thyroid nodules Clients: undisclosed Age: 5 year(s) | Start-up | Managing Dir.-CEO: Lacoste (François) [co-founder, born 1950, Eng. physics, ex-Technomed, Cilas-Alacatel, Perkin Elmer] Sc.Dir.-CSO: R&D Dir.-CMO: Yon (Sylvain) [born 1974, ESCPI, Ph.D. physics, ex-Echosens (co-founder)] Fin.Dir.-CFO: BusDev: Del Bourgo (David) [Eng. UIT Compiègne, MBA Chicago, ex-Orbotech, Advention Business Partners, General Electric Healthcare] Financers (Hist.): Truffle Ventures | 5.1 | 1.6 | Multiple | Clinical |
| TheraVectys Profile + www.theravectys.com | 2005 | IDF Paris | Discovery, Immunology Key words: Vaccines, DNA Flap Lentivirus, Veterinary Mission: to develop new vaccines derived from the DNA Flap Lentivirus technology Clients: Pharmaceutical industry (own development up to clinical trials) Age: 4 year(s) | Spin-off | Managing Dir.-CEO: Gohaud (Romain) [born 1949] Sc.Dir.-CSO: Charneau (Pierre) [Ph.D. virology, Institut Pasteur] Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€) | n.a. | n.a. | Vaccines | Preclin |
| Transgene Profile + www.transgene.fr/us | 1979 | Alsace Strasbourg | Discovery, Immunology Key words: Therapeutic vaccines, Immuno-therapy, Cancer, Infectious diseases Mission: to discover and develop gene-based therapeutic vaccines and immunotherapy products Clients: Prescribers Age: 31 year(s) | Start-up | Managing Dir.-CEO: Archinard (Philippe) [born 1959, Ph.D. Biochemistry, Eng. Chemistry, ex-Innogenetics (CEO), Biomérieux] Sc.Dir.-CSO: Bonnefoy (Jean-Yves) [Ph.D. immunology, ex-Pierre Fabre, Glaxo Wellcome] Fin.Dir.-CFO: Poncet (Philippe) [HEC, ex-Aventis CropScience, Rhône Poulenc] BusDev: Valencony (François) [HEC, ex-Mérieux, Schneider Electric] Financers (Hist.): Mérieux (53%), Institutional investors, AFM, Public | 350 (over) | 100.1 | Vaccines | Clinical |
| Trophos Profile + www.trophos.com | 1999 | Méditerranée Marseille | Discovery, Drugs Key words: Embryonic neurones, Parkinson's diseases, Huntington's diseases, Cardiac ischemia, IRIstop Mission: to develop drugs to prevent neuronal loss in patients with neurodegenerative diseases, based on proprietary screening system employing sick neurons (focused in 2009, onto neuroprotection and cardioprotection) Clients: Prescribers Age: 11 year(s) | Personal venture | Managing Dir.-CEO: Marron (Damian) [born 1962, Pharmacologist, ex-3M Pharma, Orphan Europe, Rhône Poulenc Rorer, Glaxo] Sc.Dir.-CSO: Pruss (Rebecca) [Ph.D., ex-Sanofi-Synthélabo] Med.Dir.-CMO: Abitbol (Jean-Louis) [M.D., ex-Parke Davis, Pfizer, Pierre Fabre] Fin.Dir.-CFO: Placet (Christine) [ex-Ernst & Young] BusDev: Harris (Stephen) [Ph.D., ex-GSK] Financers (Hist.): Société Générale Assets Management (SGAM), Turenne Capital Partners, Viveris Management, SOFIPACA, SOFIMAC OTC Asset Management, CM-CIC Asset Management, Blue Medical, AFM (French Muscular Dystrophy Association), Innoveris, business angels | 30.0 | 8.5 | Multiple | Clinical |
| TxCell Profile + www.txcell.com | 2001 | Méditerranée Sophia Antipolis (near Nice) | Discovery, Immunology Key words: Cell Therapy, Inflammatory, Autoimmune diseases Mission: to develop new therapies to cure inflammatory and autoimmune diseases, such as Crohn’s disease, multiple sclerosis, psoriasis or rheumatoid arthritis, by bringing regulatory T cells to the body Clients: Prescribers Age: 8 year(s) | Spin-off | Managing Dir.-CEO: Hammel (Frédéric) [born 1966, Normale Sup, MBA] Sc.Dir.-CSO: Foussat (Arnaud) [Ph.D., ex-Inserm] Med.Dir.-CMO: Forte (Miguel) [M.D., Ph.D., ex-B.M.S., Nabi Pharmaceuticals, UCB] Fin.Dir.-CFO: Sarlot (Christophe) BusDev: Dellamonica (David) [MBA, ex-Nex&Com, Polygram Universal] Financers (Hist.): Auriga Partners, AXA Private Equity, BioAm, CDC, SPEF Venture, Inserm-Transfert | 21.0 | 10.5 | Inflammation | Clinical |
| UroGene Profile + www.urogene.com | 1998 | IDF Paris | Discovery, Drugs (also, Development, Drugs) Key words: Urinary tract dysfunctions, Prostate, Bladder Cancer Mission: to develop innovative drugs in urology Clients: Pharmaceutical companies (own development up to phase III) Age: 11 year(s) | Start-up | Managing Dir.-CEO: Attali (Pierre) [born 1950, M.D., M.Sc., ex-Cerep, Molecular Engines Labs, Synthélabo] Sc.Dir.-CSO: Bienaymé (Hugues) [born 1963, Ph.D. organic chemistry, ex-Chrysalon, Rhône-Poulenc Rorer] Fin.Dir.-CFO: BusDev: Financers (Hist.): Société Générale A.M., Capricorn Venture Partners, Nuage, FCJE (CDC), Genavent, OSEO-ANVAR | n.a. | 1.5 | Cancers | Clinical |
| UROsphere Profile + www.urosphere.com | 2004 | Midi-Pyrénées Labège (near Toulouse) | Contract, Research Key words: Urinary incontinence, Benign prostatic hyperplasia (BPH), Sexual dysfunctions, Renal disorders Mission: to provide third parties with research preclinical services for urology and renal pathologies Clients: Pharmaceutical industry Age: 5 year(s) | Spin-off | Managing Dir.-CEO: Lluel (Philippe) [born 1966, Ph.D. pharmacology] Sc.Dir.-CSO: Palea (Stefano) [born 1962, Ph.D. pharmaceutical chemistry, ex-Sanofi-Aventis, Glaxo-Wellcome] Fin.Dir.-CFO: BusDev: HR.Dir: Mignotte-Darmon (Brigitte) [DESS Management] Financers (Hist.): privately owned (registered capital 2006 = 0.13 M€) | n.a. | n.a. | Multiple | Preclin |
| Urrma Profile + www.urrma.eu | 2001 | Méditerranée Aubagne (near Marseille) | Discovery, Drugs (also, Discovery, Diagnostics) Key words: Antiretroviral, HIV, B-lymphocytes, R7V technology Mission: to develop and bring to market innovative products in treatment and pronostic of HIV infected patients based on Professor Jean-Claude Chermann’s knowledge of HIV disease Clients: Prescribers Age: 8 year(s) | Start-up | Managing Dir.-CEO: Chermann (Jean-Claude) [born 1939, M.D., co-discoverer of AIDS virus, Professor, ex-Institut Pasteur, Inserm] Sc.Dir.-CSO: Chermann (Jean-Claude) and Camille Haslin [Ph.D. sciences, ex-CNRS] Fin.Dir.-CFO: BusDev: Financers (Hist.): | 15.0 | 9.0 | Virus | Preclin |
| Vaxon Biotech Profile + www.vaxon-biotech.com | 2004 | IDF Évry (near Paris) | Discovery, Immunology Key words: Therapeutic vaccines, Cryptic peptides Mission: to develop innovative therapeutic vaccines for the treatment of cancer including lung, prostate, breast, renal, liver and colorectal cancer, using proprietary technology of optimized cryptic peptides Clients: Prescribers Age: 6 year(s) | Personal venture | Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)] Sc.Dir.-CSO: Kosmatopoulos (Kostas) [born 1950, M.D., Ph.D., also Chairman, ex-Inserm] Fin.Dir.-CFO: BusDev: Financers (Hist.): Génopole 1er Jour (G1J), Inserm-Transfert, privately owned | n.a. | n.a. | Vaccines | Clinical |
| Vectalys Profile + www.vectalys.com | 2005 | Midi-Pyrénées Labège (near Toulouse) | Design, Drugs (also, Contract, Resarch) Key words: Gene sequences, Gene transfer, Viral vector, Retrovirus, Lentivirus Mission: to provide third parties with a platform of retroviral (RV), lentiviral (LV) and adeno-associated virus (AAV) based vectors that efficiently introduce human gene sequences into a wide variety of human cells to knock-in or knock-down specific proteins Clients: Pharmaceutical industry Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Bouillé (Pascale) [born 1967, founder, Ph.D. molecular biology] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): pricately owned (registered capital 2006 = 0.05 M€) | n.a. | n.a. | Virus | Preclin |
| VigiCell Profile + www.vigicell.eu | 1999 | IDF Villejuif (near Paris) | Contract, Services Key words: Predictive toxicology, Genotoxicity, Toxichip, Angiogenesis Mission: to provide third parties with services designing, performing and interpreting predictive toxicology tests, based on proprietary in-house developed tools Clients: Research labs Age: 10 year(s) | Personal venture | Managing Dir.-CEO: Gilbert (Jean-Emmanuel) [born 1967, Ph.D.] Sc.Dir.-CSO: Fin.Dir.-CFO: BusDev: Financers (Hist.): privately owned, with a minority share by SucSeed (a specialist biotech & IT seed fund) and Addes | n.a. | 0.5 | Studies | Subcontractor |
| Vivalis Profile + www.vivalis.com | 1999 | Bretagne Nantes | Design, Manufacture (also, Discovery, Immunology) Key words: Vaccines, Flu, Viral diseases, EBx Cell line, Therapeutic protein, Cell Culture Mission: to provide innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and to develop own vaccines and drugs in order to prevent and treat viral diseases Clients: Pharmaceutical industry (own development up to clinical trials) Age: 10 year(s) | Start-up | Managing Dir.-CEO: Grimaud (Franck) [co-founder, born 1966, MBA] Sc.Dir.-CSO: Mehtali (Majid) [Ph.D., ex-Deltagen, Transgene, Rhône Mérieux] Fin.Dir.-CFO: Rousseau (Philippe) [HEC, ex-Exonhit, Valigen, Genset, Mars, Paribas] BusDev: Miniou (Pierre) [Ph.D., ex-Pierre Fabre, Transgene] Financers (Hist.): Grimaud-La Corbière Group, Public Note : company legal domiciliation : Roussay (49) | 39.5 | 29.0 | Multiple | Preclin |
| XenTech Profile + www.xentech.eu | 2006 | IDF Évry (near Paris) | Contract, Research (also, Discovery, Diagnostics) Key words: Theranostics, Preclinical oncology, Tumor models Mission: to provide specialized services in predictive preclinical oncology, to develop own treatment diagnostics derived from patient-derived tumor xenografts Clients: Pharmaceutical industry, Biotechs, Research labs Age: 3 year(s) | Spin-off | Managing Dir.-CEO: Coulomb (Bertrand) [born 1955] Sc.Dir.-CSO: Judde (Jean-Gabriel) [co-founder, born 1954, Ph.D., ex-MD Anderson Cancer Center, NCI, Institut Curie, also board chairman] Oper.Dir.-COO: Leuraud (Pascal) [co-founder, Ph.D.] Fin.Dir.-CFO: BusDev: Beurdeley (Arnaud) [Ms. biology] Financers (Hist.): privately owned (registered capital 2007 = 0.05 M€), Aurinvest Capital 2 | 0.6 | 0.6 | Cancers | Preclin |
| Zeta Biotech Profile + www.zetabiotech.com | 2005 | Bretagne Lannion | Development, Diagnostics Key words: Electrophoresis, Molecular gel, UltraPag Mission: to develop and market a new generation of electrophoresis supports (UltraPag gel is the first deshydrated electrophoresis support worldwide) Clients: Research labs, Pharmaceutical industry, Chemical industry Age: 4 year(s) | Personal venture | Managing Dir.-CEO: Guyader (Antony) [co-founder, born 1976, M.Sc. biochemistry] Sc.Dir.-CSO: Fin.Dir.-CFO: Viola (Bruno) [co-founder, Sup de Co Brest, ex-Corvis, Alcatel, Pirelli/Cisco] BusDev: Financers (Hist.): privately-owned (founders, 60%), private investors, public | n.a. | 1.5 | Testing | Trade |
Actualisation / Updating: Mar 10 2010
